WO2018029604A1

WO2018029604A1 - C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors

Info

Publication number: WO2018029604A1
Application number: PCT/IB2017/054843
Authority: WO
Inventors: Parthasaradhi Reddy BANDI; Rathnakar Reddy KURA; David Krupadanam GAZULA LEVI; Bhaskar Reddy KASIREDDY; Carl Thomas Wild; David Eugene Martin; Theodore John Nitz
Original assignee: Hetero Labs Limited
Priority date: 2016-08-08
Filing date: 2017-08-08
Publication date: 2018-02-15

Abstract

The present invention relates to C-3 novel triterpenone with C-17 reverse amide compounds of Formula (I); and pharmaceutically acceptable salts thereof, wherein ring Formula (II), R₁, R₂, R₃, R₄, R₅, R₆, R₇, 'n' and 'm' are as defined in Formula (I). The invention also relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Description

C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS

HIV INHIBITORS"

This application claims the benefit of Indian provisional application no 201641027006 filed on 8^th August 2016 which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to C-3 novel triterpenone with C-17 reverse amide derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

BACKGROUND OF THE INVENTION

The Human Immunodeficiency Virus (HIV) has now been established as the causative agent of the Acquired Immunodeficiency Syndrome (AIDS) for over 20 years (Science 1983, 220, 868-871; N.Eng.J.Med.1984, 311, 1292-1297). AIDS is characterized by the destruction of the immune system, particularly of CD4+T-cells. HIV is a retrovirus, and the HIV life cycle encompasses several crucial steps, starting from the attachment of the virus to the host cell membrane and finishing with the release of progeny virons from the cell.

The natural compound betulinic acid, isolated from Syzygium clavifolium and several other plant species was found to possess anti-HIV activity. Chemical modifications were undertaken by several research groups in an attempt to identify potent anti-HIV agents by making semi- synthetic analogs of betulinic acid, leading to the discovery of Bevirimat as a compound with a novel mechanism of action (J. Nat. Prod. 199457(2):243-7; J. Med. Chem. 1996, 39(5), 1016). Further studies shown that Bevirimat acts by disrupting Gag processing (Proc. Natl. Acad. Sci. USA 2003, 100(23): 13555-60; Antimicrob. Agents. Chemother. 2001, 45(4), 1225-30; J. Virol. 2004, 78(2): 922-9; J. Biol. Chem. 2005, 280 (51): 42149-55; J. Virol. 2006, 80(12): 5716-22) and to be a first-in-class maturation inhibitor with a potent activity against HIV-1. Bevirimat went up to phase 2 clinical trials, in clinic despite optimal plasma concentrations, not all patients given Bevirimat have a robust viral load reduction. It was reported that non-re spondant patients had more frequent base line Gag polymorphisms near the capsid SP-1 cleavage site than responders. (HIV gag polymorphism determines treatment response to Bevirimat. XVII international HIV drug resistance work shop June 10- 14, 2008, Sitges, Spain).

Encouraged by these developments, medicinal chemists started exploring betulinic acid derivatives and related compounds intensively for their therapeutic activities. For example, WO 2014/093941 describes pharmaceutical compositions of betulin derivatives; WO 2009/082819 describes preparation of 17-amino lupane derivatives as anti-HIV agents; WO 2013/117137 describes lupane triterpenoids derivatives and pharmaceutical use thereof; WO 2013/020245 describes carbonyl derivatives of betulin; WO 2009/082818 describes preparation of C21-keto lupane derivatives for the treatment of HIV infections; WO 2011/100308 describes preparation of betulin derivatives for treatment of HIV-1; WO 2013/090664 describes preparation of betulin derivatives for the treatment of HIV; WO 2013/091144 describes preparation of propenoate derivatives of betulin useful for the treatment of HIV; WO 2013/090683 describes preparation of betulin propenoate derivatives for the treatment of HIV.

Some additional references disclose betulinic acid related compounds. For example, WO 2007/141383 describes betulin derivatives as antifeedants for plant pests; US 6670345 describes use of betulinic acid and its derivatives for inhibiting cancer growth and process for the manufacture of betulinic acid; WO 2002/091858 describes anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods of preparation and use; WO 2000/046235 describes preparation of novel betulinic acid derivatives for use as cancer growth inhibitors; WO 2007/141392 describes cosmetic and pharmaceutical compositions comprising betulonic acid and betulin derivatives; and Pharmaceutical Chemistry Journal, 2002, 36(9), 29-32 describes synthesis and anti-inflammatory activity of new acylated betulin derivatives.

Given the fact of the world wide epidemic level of AIDS, there is a strong continued need for new effective drugs for treatment of HIV infected patients, disease conditions and/or disorders mediated by HIV by discovering new compounds with novel structures and/or mechanism of action(s).

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to the compounds of the formula (I):

Formula (1) wherein,

, (wherein R_b is selected from hydrogen, substituted or unsubstituted Ci-C₆ alkyl, or substituted or unsubstituted C₃-C₈ cycloalkyl);

R₂ is selected from hydrogen, or substituted or unsubstituted Ci-C₆ alkyl;

R₃ and R₄ are independently selected from substituted or unsubstituted Ci-C₆ alkyl, substituted or unsubstituted amine, substituted or unsubstituted C₃-C₈ cycloalkyl; or R3 and R4 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C₃-C₈ cycloalkyl, epoxide, oxetane, or azetidine;

R5 and R₆ are independently selected from hydrogen, substituted or unsubstituted Ci- C₆ alkyl; and R5 and R₆ are taken together to form an oxo group; or R5 and R₆ are taken together with the carbon atom to which they are attached to form a substituted or unsubs ycloalkyl;

selected from substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heteroaryl, or substituted or unsubstituted heteroarylalkyl;

R₇ at each occurrence is independently selected from hydrogen, alkyl, halo, , alkoxy, alkoxylalkoxy, haloalkyl, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heterocyclylalkyl, -0(CH₂)_p-heterocyclyl, -O- (CH₂)_q-alkylamino, or substituted or unsubstituted 4-15 membered heteroaryl; wherein the substituents are selected from alkyl, alkylsulfonyl, heterocyclyl, heterocyclylalkyl, hydroxyl, halo, or hydroxylalkyl;

'n' is an integer selected from 1-2;

'm' is an integer selected from 1-3; and

'p' and 'q' independently are an integer selected from 0-2, or pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In another aspect, the present invention relates to pharmaceutical composition comprising C-3 novel triterpenone with C-17 reverse amide derivatives and related compounds of formula (I) and processes for preparing thereof.

In yet another aspect, the present invention relates to C-3 novel triterpenone with C- 17 reverse amide derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the present invention relates to C-3 novel triterpenone with C-17 reverse amide derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Each embodiment is provided by way of explanation of the invention, and not by way of limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the compounds, compositions, and methods described herein without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be applied to another embodiment to yield a still further embodiment. Thus it is intended that the present invention include such modifications and variations and their equivalents. Other objects, features, and aspects of the present invention are disclosed in, or are obvious from, the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not to be construed as limiting the broader aspects of the present invention.

In one embodiment, the present invention relates to compounds of formula (I):

Formula (1) wherein,

, (wherein R is selected from hydrogen, substituted or unsubstituted Q-C₆ alkyl, or substituted or unsubstituted C₃-C₈ cycloalkyl);

R₂ is selected from hydrogen, or substituted or unsubstituted Ci-C₆ alkyl;

R₃ and R₄ are independently selected from substituted or unsubstituted Q-C₆ alkyl, substituted or unsubstituted amine, substituted or unsubstituted C₃-C₈ cycloalkyl; or R3 and R4 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C₃-C₈ cycloalkyl, epoxide, oxetane or azetidine;

R5 and R₆ are independently selected from hydrogen, substituted or unsubstituted Q- C₆ alkyl; and R5 and R₆ are taken together to form an oxo group; or R5 and R₆ are taken together with the carbon atom to which they are attached to form a substituted or unsubs ycloalkyl;

'n' is an integer selected from 1-2;

'm' is an integer selected from 1-3; and

In another embodiment, the present invention relates to compounds of formula (IA):

wherein,

R₂ is selected from hydrogen, or substituted or unsubstituted Q-C₆ alkyl;

R₃ and R₄ are independently selected from substituted or unsubstituted Q-C₆ alkyl, substituted or unsubstituted amine, substituted or unsubstituted C₃-C₈ cycloalkyl; or R₃ and R4 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C₃-C₈ cycloalkyl, epoxide, oxetane, or azetidine;

R₇ at each occurrence is independently is selected from hydrogen, alkyl, halo, , alkoxy, alkoxylalkoxy, haloalkyl, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heterocyclylalkyl, -0(CH₂)_p-heterocyclyl, -O-

(CH₂)_q-alkylamino, or substituted or unsubstituted 4-15 membered heteroaryl; wherein the substituents are selected from alkyl, alkylsulfonyl, heterocyclyl, heterocyclylalkyl, hydroxyl, halo, or hydroxylalkyl;

'n' is an integer selected from 1-2;

'm' is an integer selected from 1-3; and

In yet another embodiment, the present invention relates to compounds of formula

(IB):

wherein,

R₇ at each occurrence is independently selected from hydrogen, alkyl, halo, , alkoxy, alkoxylalkoxy, haloalkyl, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heterocyclylalkyl, -0(CH₂)_p-heterocyclyl, -O- (CH₂)_q-alkylamino, or substituted or unsubstituted 4-15 membered heteroaryl; wherein the substituents are selected from alkyl, alkylsulfonyl, heterocyclyl, heterocyclylalkyl, hydroxyl, halo, or hydroxylakyl;

'n' is an integer selected from 1-2;

'm' is an integer selected from 1-3; and

'p' and 'q' independently are an integer selected from 0-2, or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

(IC):

wherein,

R₂ is selected from hydrogen, or substituted or unsubstituted Ci-C₆ alkyl;

R₃ and R₄ are independently selected from substituted or unsubstituted Ci-C₆ alkyl, substituted or unsubstituted amine, substituted or unsubstituted C₃-C₈ cycloalkyl; or R₃ and R4 are taken together with the carbon atom to which they are attached to form a substituted or unsubs ycloalkyl, epoxide, oxetane, or azetidine;

selected from substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heteroaryl or substituted, or unsubstituted heteroarylalkyl;

R₇ at each occurrence independently is selected from hydrogen, alkyl, halo, alkoxy, alkoxylalkoxy, haloalkyl, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heterocyclylalkyl, -0(CH₂)_p-heterocyclyl, -O- (CH₂)_q-alkylamino, or substituted or unsubstituted 4-15 membered heteroaryl; wherein the substituents are selected from alkyl, alkylsulfonyl, heterocyclyl, heterocyclylalkyl, hydroxyl, halo, or hydroxylakyl;

'm' is an integer selected from 1-3; and

'p' and 'q' independently are an integer selected from 0-2, or

It should be understood that the formula (I), (IA), (IB) and (IC) structurally encompasses all stereoisomers, including enantiomers, diastereomers, racemates, and combinations thereof which may be contemplated from the chemical structure of the genus described herein.

It should be understood that the formula (I), (IA), (IB) and (IC) structurally encompasses all tautomers. Also contemplated that the prodrugs of the compounds of the formula (I) includes esters of the compounds.

The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.

According to one embodiment, there is provided a compound of formula (I), wherein

Ri is

According to another embodiment there is provided a compound of formula (I), wherein R₂ is hydrogen.

According to yet another embodiment there is provided a compound of formula (I), wherein R₃ and R₄ are methyl.

According to yet another embodiment there is provided a compound of formula (I), wherein R5 and R₆ together form an oxo (keto).

According to yet another embodiment there is provided a compound of formula (I), wherein 'n' is 1.

According to yet another embodiment there is provided a compound of formula (I), wherein ring is phenyl, lH-benzo[d] imidazole, pyridine or lH-pyrazole.

According to yet another embodiment there is provided a compound of formula (I), wherein R₇ is hydrogen, methyl, methoxy, chloro, 2-methoxyethan-l-ol, morpholine, thiomorpholine 1,1 -dioxide, 4-(piperidin-4-yl)morpholine, l-methylpiperidin-4-ol, 4- methylmorpholine, (R)-tetrahydrofuran-3-ol, 2-morpholinoethan-l-ol, 1,4- dimethylpiperazine, piperidin-4-ol, 4-(2-hydroxyethyl)thiomorpholine 1,1 -dioxide, piperidin- 4-ol, 2-(pyrrolidin-l-yl)ethan-l-ol, 2-(piperidin-l-yl)ethan-l-ol, or 2-(dimethylamino)ethan- l-ol.

According to yet another embodiment there is provided a compound of formula (I), wherein 'm' is 1.

According to yet another embodiment there is provided a compound of formula (I), wherein 'm' is 2.

In certain embodiments, the compounds of formula (I) can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses. The present invention is meant to include all suitable isotopic variations of the compounds of generic formula (I). For example, different isotopic forms of hydrogen (H) include protium ( 1H) and deuterium ( 2 H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may provide certain therapeutic advantages, such as increasing in vivo half -life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.

Isotopically-enriched compounds of formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates. In one embodiment, a compound of formula (I) has one or more of its hydrogen atoms replaced with deuterium.

The representative compounds according to the present invention including the compounds disclosed in the experimental section are illustrative in nature only and are not intended to limit to the scope of the invention. (Nomenclature wherever applicable has been generated from ChemBioDraw Ultra 13.0 version).

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-(4-methoxy benzamido)-2-methylpropanamido)-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a, 8,9,10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)- 2,2-dimethylcyclobutane-l-carboxylic acid (Example 1),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-methoxy benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5, 5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy) carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 2),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-(4-(2- methoxyethoxy)benzamido)-2-methylpropanamido)-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4, 5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 3),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(2-methyl-lH-benzo[d]imidazole-5-carboxamido)propanamido) -2-oxo-3,3a,4,5,5a,5b, 6,7 ,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 4), (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(lH-benzo[d]imidazole- 2-carboxamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo-3,3a,4, 5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 5),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)

pentamethyl-3a-(2-methyl-2-(6-morpholinonicotinamido)propanamido)-2-oxo-3,3a,4,5,5a,5 6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy) carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 6),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(3-methyl-lH-pyrazole-5-carboxamido)propanamido)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 7),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(6-(l,l-dioxidothio morpholino)nicotinamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 8),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(4-morpholinopiperidin-l-yl)benzamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 9),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-((4-hydroxypiperidin- l-yl)methyl)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 10),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(morpholinomethyl)benzamido)propanamido)-2-oxo-3,3a,4, 5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 11),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(((R)-tetrahydrofuran-3-yl)oxy)benzamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 12),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(2-morpholinoethoxy)benzamido)propanamido)-2-oxo-3,3a, 4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadeca ydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 13)

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-((4-methylpiperazin-l-yl)methyl)benzamido)propanamido)- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 14),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 15),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(4-methylpiperazin-l-yl)benzamido)propanamido)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 16),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-(4-hydroxypiperidin- l-yl)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a, 4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 17),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo-3,3a,4,5, 5a,5b,6,7,7a,8, 9,10,11,1 la,l lb, 12,13, 13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 18),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-methoxy ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3, 3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 19),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(((R)-tetra hydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-penta methyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 20),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- morpholinoethoxy)benzamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-penta methyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 21),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-((l-(tert-butoxy carbonyl)piperidin-4-yl)oxy)-4-chlorobenzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro -2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 22),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-(dimethyl amino)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 23), and

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 24),

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (Example 25), and

sodium (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- (piperidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylate (Example 26), or

pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, including hydrates and prodrugs of compounds are also contemplated.

In further yet another embodiment, the compounds of formula (I) structurally encompasses all stereoisomers, enantiomers and diastereomers, and pharmaceutically acceptable salts that may be contemplated from the chemical structure of the general formula (I) described herein. The absolute configuration at an asymmetric atom is specified by either R or S. Resolved compounds whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 5%, in particularly less than 2% or 1 % of the other isomers. Thus when a compound of formula (I) is for instance specified as (R), this means that the compound is substantially free of (S) isomer; when the compound of formula (I) is for instance specified as E, this means that the compound is free of the Z isomer; when the compound of formula (I) is for instance specified as cis isomer, this means that the compound is free of the trans isomer.

In further yet another embodiment, the prodrugs of present invention are the compounds of formula (I) and its pharmaceutically acceptable salts, stereoisomers, solvates thereof containing an hydroxyl group; wherein hydrogen atom of the hydroxyl group are replaced with (Ci-C₆)alkanoyloxymethyl, l-((Ci-C₆)alkanoyloxy)ethyl, 1 -methyl- l-((Ci- C₆)alkanoyloxy)ethyl, (Ci-C₆)alkoxycarbonyloxymethyl, N-(Ci-C₆)alkoxycarbonyl aminomethyl, succinoyl, (Ci-C₆)alkanoyl, a-amino(Ci-C₄)alkyl, a-amino(Ci-C₄)alkylene- aryl, arylacyl and a-aminoacyl, where each a -aminoacyl group is independently selected from the naturally occurring L-amino acids, or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

In further yet another embodiment, the prodrugs of present invention are the compounds of formula (I) and its pharmaceutically acceptable salts, stereoisomers, hydrates, solvates thereof containing an amine group; wherein one or more hydrogen atoms of the amine group is replaced with (Ci-C₆)alkylcarbonyl, (Ci-C₆)alkoxycarbonyl, aminocarbonyl, (C3-C₆)cycloalkylcarbonyl, benzylcarbonyl and the like.

The present invention also provides a pharmaceutical composition that includes at least one compound according to formula (I) and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Specifically, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound according to formula (I). The compound(s) present in the composition may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or may be diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, or other container.

The compounds and pharmaceutical compositions described herein are useful in the treatment of diseases, conditions and/or disorders mediated by viral infections. The present invention further provides a method of treating a disease, condition and/or disorder mediated by viral infections in a subject in need thereof by administering to the subject one or more compounds described herein in a therapeutically effective amount to treat that infection, specifically in the form of a pharmaceutical composition.

In another aspect, the present invention relates to combinations comprising a compound of the formula (I) and a second therapeutic agent that is an anti-HIV agent, an anti-HCV agent or anti-TB agents.

In another aspect, the present invention relates to pharmaceutical compositions comprising the compound of formula (I) and one or more second anti-HIV agents and their pharmaceutically acceptable salts and stereoisomers thereof.

In another aspect, the present invention relates to combinations comprising a compound of the formula (I) and one or more second anti-HIV agents selected from the group consisting of Protease inhibitors, Integrase inhibitors, Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion/Entry inhibitors, Pharmacokinetic enhancers, and combinations thereof.

The present invention relates to methods of treatment of HIV infection, AIDS, and AIDS-related conditions by administering to a subject a compound of formula (I) and one or more second therapeutic agents selected from the group consisting of Protease inhibitors, Integrase inhibitors, Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion/Entry inhibitors, Pharmacokinetic enhancers, and combinations thereof.

In another aspect, the present invention relates to combinations comprising a compound of the formula (I) and one or more second anti-HIV agents wherein the second anti-HIV agent is Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Zidovudine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Nelfinavir, Ritonavir, Cobicistat, Saquinavir, Tipranavir, Enfuvirtide, Maraviroc, Fostemsavir, Dolutegravir, Elvitegravir, Raltegravir, Bictegravir, Cabotegravir or a combination thereof.

In another aspect of the present invention provides a method for preventing; ameliorating or treating a HIV mediated disease, disorder or syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of the invention. The invention further provides a method, wherein the HIV mediated disease, disorder or syndrome is like AIDS, AIDS related complex, or a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss, or a retroviral infection genetically related to AIDS.

Anti HIV inhibitory potential of the compounds of present invention may be demonstrated by any one or more methodologies known in the art, such as by using the assays described in Mossman T, December 1983, Journal of immunological methods, 65 (1- 2), 55-63 and SPC Cole, cancer chemotherapy and Pharmacology, 1986, 17, 259-263.

The following definitions apply to the terms as used herein:

The terms "halogen" or "halo" includes fluorine, chlorine, bromine, or iodine.

The term "hydroxyl" refers to -OH.

The term "oxo" refers to -C=0.

The term "alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl).

The term "alkoxy" refers to a straight or branched hydrocarbon chain with oxygen radical consisting carbon and hydrogen atoms, containing saturation or unsaturation, having from one to eight carbon atoms, and which is attached through oxygen atom to the rest of the molecule by a single bond, e.g., methyloxy, ethyloxy, n-propyloxy, 1-methylethyloxy (isopropyloxy), n-butyloxy, n-pentyloxy, and 1,1-dimethylethyloxy (t-butyloxy).

The term "alkoxylalkoxy" refers to a straight or branched hydrocarbon chain with oxygen radical consisting carbon atom, hydrogen atom and alkoxy groups, containing saturation or unsaturation, having from one to eight carbon atoms, and which is attached through oxygen atom to the rest of the molecule by a single bond, e.g., 2- (methyloxy)ethyloxy, 2-(ethyloxy)ethyloxy, 2-(n-propyloxy)ethyloxy, and 3- (isopropyloxy)butyloxy.

The term "alkyl sulfonyl" refers to a group designates an "alkyl-S0₂-" group, wherein alkyl is as defined above. Examples of preferred alkyl sulfonyl groups of the invention include methyl sulfonyl, ethyl sulfonyl and propyl sulfonyl.

The term "amine" refers to an organic compounds and functional groups that contain a basic nitrogen atom with a lone pair. Amines are derivatives of ammonia, wherein one or more hydrogen atoms have been replaced by a substituent such as an alkyl or aryl group these may respectively be called alkylamines and arylamines; amines in which both types of substituent are attached to one nitrogen atom may be called alkylarylamines. Important amines include amino acids, trimethylamine, and aniline. The term "alkylamino" refers to any alkyl derivative of an amino radical more specifically dimethylamino.

The term "cycloalkyl" denotes a non-aromatic mono or multicyclic ring system of from 3 to about 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups, e.g., bicyclo [2.2.1] heptane and spirobicyclic groups, e.g., spiro (4,4) non-2-yl.

The term "aryl" refers to an aromatic radical having from 6 to 14 ring carbon atoms;In certain embodiments the term "aryl" refers to an partially unsaturated 6 to 14 membered ring. In preferred embodiments the aryl ring can be monocyclic, bicyclic and tricyclic, when aryl is bicyclic or tricyclic ring, one or more of the rings can be saturated or partially saturated. Exemplary compounds of aryl are not limited to phenyl, naphthyl, indeneyl, indanyl, tetrahydronapthyl, indanyl, biphenyl, 9H-fluorenyl and 2,3-dihydro-lH-indenyl and the like.

The term "haloalkyl" refers to alkyl group (as defined above) is substituted with one or more halogens. A monohaloalkyl radical, for example, may have a chlorine, bromine, iodine or fluorine atom. Dihalo and polyhaloalkyl radicals may have two or more of the same or different halogen atoms. Examples of haloalkyl include, but are not limited to, chloromethyl, dichloromethyl, trichloromethyl, dichloroethyl, dichloropropyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, difluoro chloromethyl, dichloro fluoromethyl, difluoroethyl, difluoropropyl and the like.

The terms "heterocyclyl" and "heterocyclic ring" refer to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heterocyclic or heteroaryl). Examples of such heterocyclic ring radicals include, but are not limited to, tetrazoyl, tetrahydroisouinolyl, piperidinyl, piperazinyl, benzo[d][l,3]dioxole, 2,3-dihydrobenzo[b][l,4]dioxine, 2-oxopiperazinyl, 2- oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, quinoxalinyl, pyrrolyl, 4- piperidonyl, pyrrolidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxetane, oxazolyl, oxazolinyl, oxazolidinyl, oxadiazolyl, 1,2,4-oxadiazolyl, triazolyl, isoxazolyl, isoxasolidinyl, morpholinyl, tetrahydrofuranyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzothiazolyl, benzooxazolyl, furyl, tetrahydrofurtyl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiomorpholine 1,1 -dioxide, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, azetidinyl, oxadiazolyl. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.

The term "heterocyclylalkyl" refers to a heterocyclic ring radical directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.

The term "heteroaryl" refers to an aromatic heterocyclic ring radical or partially saturated ring radical. In preferred embodiments the heteroaryl ring can be monocyclic, bicyclic and tricyclic, when heteroaryl ring is bicyclic or tricyclic ring, one or more of the rings can be saturated or partially saturated rings. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. The heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems. Examples of such heteroaryl rings include, but are not limited to lH-benzo[d]imidazolyl, pyridinyl, pyrazolyl, lH-indolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, benzo[d][l,3]dioxolyl, 2,3- dihydrobenzo[b][l,4]dioxinyl, 1,3,4-thiadiazolyl, lH-l,2,4-triazolyl, thiazolyl, imidazolyl, thiophenyl, and quinoxalinyl.

The term "heteroarylalkyl" refers to a heteroaryl ring radical directly bonded to an alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.

The term "hydroxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1- (hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3- dihydroxypropyl, 1 -(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl.

"Substituted" refers to 1-3 substituents on the same position or on different positions with the same groups or different groups. Unless otherwise specified, the term "substituted" as used herein refers to substitution with any one or any combination of the following substituents: hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, s substituted or unsubstituted amino, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or substituted or unsubstituted heterocyclic ring. The substituents in the afore mentioned "substituted" groups cannot be further substituted. For example, when the substituent on "substituted alkyl" is "substituted aryl", the substituent on "substituted aryl" cannot be "substituted alkenyl".

The term "stereoisomer" or "stereoisomers" refer to compounds that differ in the chirality of one or more stereo centers. Stereoisomers include enantiomers and diastereomers.

The term "tautomer" refer to alternate forms of a compound that differ in the position of a proton, such as but are not limited to, enol-keto, imine-enamine tautomers, or the like or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring - NH- moiety and a ring =N- moiety or the like such as but are not limited to, pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

The term "regioisomer" or "positional isomer" refer to that have the same carbon skeleton and the same functional groups but differ from each other in the location of the functional groups on or in the carbon chain.

The term "prodrug" denotes a derivative of a compound, which derivative, when administered to warm -blooded animals, e.g. humans, is converted into the compound (drug). The enzymatic and/or chemical hydrolytic cleavage of the compounds of the present invention occurs in such a manner that the proven drug form (parent carboxylic acid drug) is released, and the moiety or moieties split off remain nontoxic or are metabolized so that nontoxic metabolic products are produced. For example, a carboxylic acid group can be esterified, e.g., with a methyl group or ethyl group to yield an ester. When an ester is administered to a subject, the ester is cleaved, enzymatically or non-enzymatically, reductively, oxidatively, or hydrolytically, to reveal the anionic group. An anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which are cleaved to reveal an intermediate compound which subsequently decomposes to yield the active compound. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

The term "treating" or "treatment" of a state, disease, disorder or condition includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disease, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disease, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disease, disorder or condition;

(2) inhibiting the state, disease, disorder or condition, i.e., arresting or reducing the development of the state, disease, disorder or condition or at least one clinical or subclinical symptom thereof; or

(3) relieving the state, disease, disorder or condition, i.e., causing regression of the state, disease, disorder or condition or at least one of its clinical or subclinical symptoms.

The benefit to a subject receiving treatment is either statistically significant or at least perceptible to the subject or to the physician.

The term "subject" includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).

A "therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a state, disease, disorder or condition, is sufficient to effect such treatment. The "therapeutically effective amount" will vary depending on the compound, the state, disease, disorder or condition and its severity and the age, weight, physical condition and responsiveness of the subject receiving treatment.

The compounds of the present invention may form salts. Non-limiting examples of pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases, salts of organic bases, salts of chiral bases, salts of natural amino acids and salts of non-natural amino acids. Certain compounds of the present invention are capable of existing in stereoisomeric forms (e.g., diastereomers, enantiomers, racemates, and combinations thereof). With respect to the overall compounds described by the Formula (I), the present invention extends to these stereoisomeric forms and to mixtures thereof. To the extent prior art teaches synthesis or separation of particular stereoisomers, the different stereoisomeric forms of the present invention may be separated from one another by the methods known in the art, or a given isomer may be obtained by stereo specific or asymmetric synthesis. Tautomeric forms and mixtures of compounds described herein are also contemplated.

Pharmaceutically acceptable solvates includes hydrates and other solvents of crystallization (such as alcohols). The compounds of the present invention may form solvates with low molecular weight solvents by methods known in the art. PHARMACEUTICAL COMPOSITIONS

The pharmaceutical compositions provided in the present invention include at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Specifically, the contemplated pharmaceutical compositions include a compound(s) described herein in an amount sufficient to treat viral infection in a subject.

The subjects contemplated include, for example, a living cell and a mammal, including human. The compound of the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, or other container.

Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters, and polyoxyethylene.

The carrier or diluent may include a sustained release material, such as, for example, glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, emulsifying agents, suspending agents, preserving agents, salts for influencing osmotic pressure, buffers, sweetening agents, flavoring agents, colorants, or any combination of the foregoing. The pharmaceutical composition of the invention may be formulated so as to provide quick-, sustained-, or delayed-release of the active ingredient after administration to the subject by employing procedures known in the art.

The pharmaceutical compositions described herein may be prepared, e.g., as described in Remington: The Science and Practice of Pharmacy, 20^th Ed., 2003 (Lippincott Williams & Wilkins). For example, the active compound can be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampule, capsule, or sachet. When the carrier serves as a diluent, it may be a solid, semi- solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound.

The pharmaceutical compositions may be in conventional forms, for example, capsules, tablets, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present invention may be formulated so as to provide desired release profile.

The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal, parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic (such as with an ophthalmic solution) or topical (such as with a topical ointment). The oral route is specifically suitable.

Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Exemplary carriers for tablets, dragees, or capsules include lactose, cornstarch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

A typical tablet that may be prepared by conventional tableting techniques.

Liquid formulations include, but are not limited to, syrups, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions.

For parenteral application, particularly suitable are injectable solutions or suspensions, specifically aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

METHODS OF TREATMENT

The present invention provides compounds and pharmaceutical formulations thereof that are useful in the treatment of diseases, conditions and/or disorders mediated by viral infections. The connection between therapeutic effect and antiviral is illustrated. For example, PCT publication Nos. WO 01//07646, WO 01/65957, or WO 03/037908; US publication Nos. US 4,598,095 or US 2002/0068757; EP publication Nos. EP 0989862 or EP 0724650; Bioorganic & Medicinal Chemistry Letters, 16, (6), 1712-1715, 2006; and references cited therein, all of which are incorporated herein by reference in their entirety and for the purpose stated.

The present invention further provides a method of treating a disease, condition and/or disorder mediated by viral infections in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention. Diseases, conditions, and/or disorders that are mediated by viral infections are believed to include, but are not limited to, HIV infection, HBV, HCV, a retroviral infection genetically related to HIV, AIDS, inflammatory disease, respiratory disorders (including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis and chronic sinusitis), inflammatory bowel disease (including Crohn's disease and ulcerative colitis), multiple sclerosis, rheumatoid arthritis, graft rejection (in particular but not limited to kidney and lung allografts), endometriosis, type I diabetes, renal diseases, chronic pancreatitis, inflammatory lung conditions, chronic heart failure and bacterial infections (in particular but not limited to tuberculosis).

The compounds of the present invention can obtain more advantageous effects than additive effects in the prevention or treatment of the above diseases when using suitably in combination with the available drugs. Also, the administration dose can be decreased in comparison with administration of either drug alone, or adverse effects of co administrated drugs other than antiviral can be avoided or declined.

METHODS OF PREPARATION

The compounds described herein may be prepared by techniques known in the art. In addition, the compounds described herein may be prepared by following the reaction sequence as depicted in below schemes. Further, in the following schemes, where specific bases, acids, reagents, solvents, coupling agents, etc., are mentioned, it is understood that other bases, acids, reagents, solvents, coupling agents etc., known in the art may also be used and are therefore included within the present invention. Variations in reaction conditions, for example, temperature and/or duration of the reaction, which may be used as known in the art, are also within the scope of the present invention. All the stereoisomers of the compounds in these schemes, unless otherwise specified, are also encompassed within the scope of this invention.

Compounds of the present invention can be synthesized from naturally occurring Betulin. Key intermediates required for synthesizing analogues are either commercially available or can be prepared by the methods published in the literature. For example, the key intermediates in the present invention were prepared by modifying the procedures published in Journal of organic chemistry 2010, 75, 1285-1288; Journal of organic chemistry 2000, 65, 3934-3940; Tetrahedron: asymmetry 2008, 19, 302-308; or Tetrahedron: asymmetry 2003, 14, 217-223. Another embodiment of the present invention provides process for preparation of the compounds of general formula (I) are set forth in the below generalized schemes. One of skill in the art will recognize that below generalised schemes can be adapted to produce the compounds of general formula (I) and pharmaceutically acceptable salts of compounds of general formula (I) according to the present invention. Wherein all symbols/variables are as defined earlier unless otherwise stated.

General Synthetic Procedures:

Scheme-1:

The compounds of formula (I) (wherein, R₂, R₃, R₄, R5, R₆ and R₇ are same as defined above) can be prepared as described in Scheme 1. The C-3 & C-28 di hydroxy compounds of formula (i) can be protected in different ways like

(a) With a suitable ester forming reagents such as anhydrides with or without addition of base or solvent or catalyst under heating conditions or

(b) with a suitable ester forming reagents such as anhydrides, acid halides or mixed anhydrides or the like in the presence of base such as triethylamine (TEA) or N,N- diisopropylethylamine (DIPEA) or pyridine or the like in solvents such as dichloromethane (DCM) or tetrahydrofuran (THF) or toluene or the like with or without addition of catalyst such as 4-(Dimethylamino)pyridine (DMAP) under heating conditions or the like to give the C-3 & C-28 di hydroxy protected compounds of formula (ii) (Pi and P₂ are protecting groups such as acetyl, benzyl or the like).

The compounds of formula (ii) can be converted to the ring-E ene compounds of formula (iii) in the presence of hydrogen bromide (HBr) in acetic acid (AcOH), acetic acid (AcOH) and acetic anhydride (Ac₂0) in solvents such as toluene or benzene or xylene or the like. The ring-E ene compounds of formula (iii) can be converted to the ring-E enone compounds of formula (iv) in the presence of sodium dichromate dihydrate (Na₂Cr₂0₇.2H₂0), sodium acetate (NaOAc), acetic acid (AcOH) and acetic anhydride (Ac₂0) in solvents such as toluene or benzene or the like. The ring-E enone compounds of formula

(iv) can be selectively deprotected at C-28 to give the C-28 hydroxy compounds of formula

(v) in the presence of potassium hydroxide (KOH) or the like in the combination of solvents such as toluene: ethanol (EtOH) (1: 1) or with reagent like Aluminium isopropoxide

[Al(OCH(CH₃)₂)₃] in solvent such as 2-propanol or the like. The C-28 hydroxy compounds of formula (v) can be converted to the C-28 acid compounds of formula (vi) in the presence of oxidizing agents such as 2,2,6,6-Tetramethylpiperidine-l-oxyl (TEMPO), sodium chlorite (NaC10₂), 10% sodium hypochlorite solution (10% NaOCl), buffer such as Sodium dihydrogen phosphate (NaH₂P0₄) and inorganic bases such as sodium bicarbonate or the like in the combination of solvents such as tert-butanol (t-BuOH) and water (H₂0) or the like. The C-28 acid compounds of formula (vi) can be converted to the C-17 carbamate compounds of formula (vii) by using the reagents like diphenylphosphoryl azide (DPPA) or combination of ethylchloroformate and sodium azide (NaN₃) in the presence of bases such as triethylamine (TEA) or Ν,Ν-Diisopropylethylamine (DIPEA) or the like in the solvents such as 1,2-DCE or toluene or the like in the presence of alcohol such as 4- methoxybenzyl alcohol (PMBOH) or the like. The compounds of formula (vii) containing the carbamate group at C-17 can be deprotected to the amine compounds of formula (viii) in the presence of acidic medium such as trifluoroacetic acid (TFA) or HCl/l,4-dioxane or the like in the solvents such as dichloromethane (DCM) or chloroform (CHC1₃) or the like. The C-17 amine compounds of formula (viii) can be coupled with the acid compounds of formula (ix) in the presence of coupling reagents such as 0-(7-Azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluroniumhexafluorophosphate (HATU) or 0-(Benzotriazol-l-yl)-N,N,N',N'- tetramethyluroniumhexafluorophosphate (HBTU) or combination of l-Ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDCI) and 1-Hydroxybenzotriazole hydrate (HOBt) or the like in the presence of bases such as triethylamine (TEA) or N,N-Diisopropylethylamine (DIPEA) or the like in the solvents such as 1,2-dichloroethane (1,2-DCE) or N,N- dimethylformamide (DMF) or the like to give C-17 amide compounds of formula (x). The C- 3 hydroxy compounds of formula (xi) can be achieved by deprotection at C-3 of compounds of formula (x) in the presence of aqueous solution of inorganic bases such as Lithium hydroxide (LiOH) or sodium hydroxide (NaOH) or potassium hydroxide (KOH) or the like in the combination of solvents such as methanol (MeOH): tetrahydrofuran (THF): water (H₂0) (4:2: 1) (or) 1,4-dioxane: water (H₂0) (4: 1) or the like. The C-3 hydroxy compounds of formula (xi) can be coupled with the acid compounds of formula (xii) to give the C-3 ester compounds of formula (xiii) in different ways like

(a) The coupling of compounds of formula (xi) and (xii) with reagent like 2,4,6- trichlorobenzoyl chloride or the like in the presence of bases such as triethylamine (TEA) or Ν,Ν-Diisopropylethylamine (DIPEA) or the like and catalyst such as 4-dimethylaminopyridine (DMAP) in the solvents such as 1,2- dichloroethane (1,2-DCE) or dichloromethane (DCM) or the like.

(b) The coupling of compounds of formula (xi) and (xii) with reagent such as EDCI or the like in the presence of catalyst such as 4-dimethylaminopyridine (DMAP) or the like in the solvents such as dichloromethane (DCM) or N,N- dimethylformamide (DMF) or the like.

The compounds of formula (xiv) can be prepared by the Boc deprotection of compounds of formula (xiii) in the presence of acidic medium such as trifluoroacetic acid (TFA) or HCl/l,4-dioxane or the like in the solvents such as dichloromethane (DCM) or the like. The amine compounds of formula (xiv) can be coupled with the acid compounds of formula (xv) to obtain the compounds of formula (xvi) in different ways like

a) The coupling of compounds of formula (xiv) and (xv) with coupling reagent such as 0-(7-Azabenzotriazol-l-yl)-N,N,N^N'-tetramethyluroniumhexafluorophosphate (HATU) or 0-(Benzotriazol- l-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU) or combination of l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), and 1-Hydroxybenzotriazole hydrate (HOBt) or the like in the presence of bases such as triethylamine (TEA) or Ν,Ν-Diisopropylethylamine (DIPEA) or the like in the solvents such as 1,2-dichloroethane (1,2-DCE) or Ν,Ν-dimethylformamide (DMF) or the like. b) Reductive amination of amine (xiv) and aldehyde in the presence of reducing agents such as sodium triacetoxyborohydride (STAB) or Sodium borohydride (NaBH₄) or sodium cyanoborohydride (NaCNBH₃) or the like in the solvents such as 1,2- dichloroethane (1,2-DCE) or tetrahydrofuran (THF) or Methanol (MeOH) or Acetonitrile (CH₃CN) or the like.

c) acid chloride and amine (xiv) coupling in the presence of bases such as triethylamine (TEA), or diisopropylethylamine (DIPEA) or the like in the solvents such as dichloromethane (DCM) or the like.

d) Amine (xiv) and sodium sulphite adduct coupling in the presence of reducing agents such as sodium cyanoborohydride (NaCNBH₃) or the like in the presence of bases such as triethylamine (TEA) or the like in the solvents such as methanol (MeOH) or the like.

e) Amine (xiv) and isocyanato coupling in the presence of bases such as triethylamine (TEA) or diisopropylethylamine (DIPEA) or the like in the solvents such as tetrahydrofuran (THF) or the like.

The ester compounds of formula (xvi) can be hydrolyzed to the acid compounds of formula 1 in the presence of aqueous solution of inorganic bases such as Lithium hydroxide (LiOH) or sodium hydroxide (NaOH) or potassium hydroxide (KOH) or the like in the combination of solvents such as tetrahydrofuran (THF): methanol (MeOH) (1:1) or the like.

The abbreviations used in the entire specification may be summarized herein below with their particular meaning: DIPEA (Ν,Ν-Diisopropylethylamine); °C (degree Celsius); δ (delta); ppm (parts per million); % (percentage); DMSO-d₆ (Deuterated dimethylsulfoxide); d (Doublet); dd (Doublet of doublet); EtOH (Ethanol); EtOAc (Ethyl acetate); g or gr (gram(s)); H or H₂ (Hydrogen); HC1 (Hydrochloric acid); h or hr (Hour(s)); HATU (0-(7- Azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate); Hz (Hertz); HPLC (High-performance liquid chromatography); mmol (Millimole(s)); M (Molar); N (Normality); ml or mL (Millilitre); mg (Milligram); m (Multiplet); MHz (Megahertz); ESI- MS (Electron spray Ionization Mass spectroscopy); min (Minutes); NaOH (Sodium hydroxide); NMR (Nuclear magnetic resonance spectroscopy); s (Singlet); TEA (Triethylamine); TLC (Thin Layer Chromatography); THF (Tetrahydrofuran); tert (Tertiary), TFA (Trifluoroacetic acid); t (Triplet); IC (Inhibitory concentration), nM (Nano molar); pH (Pouvoir hydrogen); (Boc)₂0 (Di-tert-butyl dicarbonate); DCM (dichloromethane); DMF (Ν,Ν-dimethylformamide); DMAP (4-(Dimethylamino)pyridine); eq (equivalent); Ltr or L (Liter(s)); CDC1₃ (Deuterated chloroform); (Coupling constant); JAB (Coupling constant); M+H⁺ (parent mass spectrum peak plus H⁺); M+Na⁺ (parent mass spectrum peak plus sodium^"1"); NaH₂P0₄ (Sodium dihydrogen phosphate); AcOH (Acetic acid); NaCNBH₃ (Sodiumcyanoboro hydride); ABq (AB quartet); Cs₂C0₃ (Cesium carbonate); CH₃CN (Acetonitrile); HBr (Hydrogen bromide); Ac₂0 (Acetic anhydride); NaHC0₃ (Sodium bicarbonate); Na₂S0₄ (Sodium sulphate); 1,2-DCE (1,2-dichloroethane); HBTU (O- (Benzotriazol-l-yl)-N,N,N\N'-tetramethyluroniurnhexafluorophosphate); KOH (Potassium hydroxide); MeOH (methanol); EDCI (l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide); HOBt (1-Hydroxybenzotriazole); brs (broad singlet); DPPA (Diphenylphosphoryl azide), PMBOH (4-methoxybenzyl alcohol), TEMPO (2,2,6,6-Tetramethylpiperidine 1-oxyl); NaC10₂ (sodium chlorite); and BINAP (2,2'-bis(diphenylphosphino)- 1 , 1 '-binaphthyl).

EXPERIMENTAL

The present invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope of this disclosure, but rather are intended to be illustrative only. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to one of ordinary skill in the art without departing from the spirit of the present invention. Thus, the skilled artisan will appreciate how the experiments and examples may be further implemented as disclosed by variously altering the following examples, substituents, reagents, or conditions.

INTERMEDIATES

Intermediate 1: Preparation of l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-amino-2- methylpropanamido)-l-isopropyl-5a,5b,8,8 J la-pentamethyl-2-oxo-3,3aA5,5a,5b,6J,7a, 8,9J0J lJ laJ lbJ2J3, 13 a-octadecahydro-2H-cyclopentaral chry sen-9-yl) 3 -benzyl

Synthesis of2-(( tert-butoxycarbonyl)amino)-2-methylpropanoic acid:

To a stirred solution of 2-Amino-2-methylpropanoic acid (50 g, 484.87 mmol, 1.0 eq) in 1,4-dioxane (500 mL) at 0 °C was added 2N NaOH solution (500 mL) followed by di-tert- butyldicarbonate (158.55 g, 727.30 mmol, 1.5 eq). The reaction mixture was allowed to stir at room temperature for overnight. After completion of the reaction (monitored by TLC), the organic phase was evaporated under reduced pressure, reaction mixture was diluted with water (100 mL), cooled to 0 °C, pH adjusted to 5 with IN HC1 and then extracted with DCM (3x500 mL). The combined organic extracts were washed with water (500 mL) and brine solution (200 mL). The organic layer was dried over Na₂S0₄, filtered and evaporated under reduced pressure. The residue was stirred with n-hexane (500 mL) at room temperature for about 30 minutes. The solid was filtered and dried under vacuum to obtain the title compound (65 g, yield: 66%) as a white solid. 1H MR (300 MHz, CDC1₃): δ ppm 9.50 (brs, 1H), 1.53 (s, 6H), 1.44 (s, 9H); ESI-MS: m/z 226.03 (M+Na)⁺.

Step 2: Synthesis of ((lR,3aS,5aR,5bR,7aR,9S,llaR,llbR,13aR,13bR)-9-acetoxy-5a,5b,

8,8,lla-pentamethyl-l-(prop-l-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate:

To a stirred solution of (lR,3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aR,13bR)-3a- (hydroxymethyl)-5a,5b,8,8,l la-pentamethyl-l-(prop-l-en-2-yl)icosahydro-lH-cyclopenta[a] chrysen-9-ol (100 g, 225.87 mmol, 1.0 eq) in toluene (200 mL) was added acetic anhydride (170 mL) in one portion. The reaction mixture was stirred at 105 °C for 2 hours 30 minutes. After completion of the reaction (monitored by TLC), the resulting mixture contained title compound was used directly in next step without further purification.

Step 3: Synthesis of ((3aS,5aR,5bR,7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl-5a,5b, 8, 8, 1 la-pentamethyl-2, 3, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-3aH- cyclopenta[a]chrysen-3a-yl)methyl acetate:

To the above resulting mixture contained compound ((lR,3aS,5aR,5bR,7aR,9S,l laR, HbR,13aR,13bR)-9-acetoxy-5a,5b, 8,8,1 la-pentamethyl- l-(prop-l -en-2-yl)icosahydro-3aH- cyclopenta[a]chrysen-3a-yl)methyl acetate (step 2) at 105 °C, sequentially added toluene (200 mL), acetic anhydride (200 mL), acetic acid (200 mL) and HBr in acetic acid (200 mL, 33%) slowly over a period of 1.5 hours and stirred at the same temperature for another 1 hour. After completion of the reaction (monitored by TLC), the reaction mixture was cooling down to room temperature, sodium acetate (120 g) was added and evaporated under reduced pressure. The residue was stirred with water (200 mL) at room temperature for 20 minutes. The mixture was filtered and the gummy solid was washed with water (300 mL) and dried under vacuum. To this solid compound, ethanol (200 mL) was added and stirred at 0 °C for 30 minutes. The mixture was filtered, washed with ethanol (30 mL) and dried under vacuum to afford the title compound (90 g) as an off-white solid, used in next step without further purification.

Step 4: Synthesis of ((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl-5a,5b, 8,8, 11 a-pentamethyl-2-oxo-2, 3,4,5, 5a,5b,6,7, 7a,8,9, 10, 11,11 a,l lb, 12, 13,13a-octadecahydro- 3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate:

To a stirred solution of ((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate (step 3, 90.0 g, 170.84 mmol, 1.0 eq) in toluene (540 mL) was added sodium acetate (78.0 g, 973.56 mmol, 5.7 eq), sodium dichromate dihydrate (61.0 g, 205.01 mmol, 1.2 eq), acetic anhydride (180 mL) and acetic acid (270 mL). The reaction mixture was stirred at 60 °C for 14 hours. After completion of the reaction (monitored by TLC), the reaction mixture was cooling down, diluted with water (1000 mL) and extracted with ethyl acetate (2x1000 mL). The organic phase was washed successively with saturated solution of sodium carbonate (1000 mL) and brine solution (500 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. To this residue, methanol (200 mL) was added, stirred at 0 °C for 1 hour, filtered and dried under vacuum to obtain the title compound (65.0 g, yield: 70.42%) as an off-white solid, used in next step without further purification. Step 5: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(hydroxymethyl)-l-isopropyl -5 a, 5b, 8, 8, 1 la-pentamethyl-2-oxo-3,3a,4, 5, 5 a, 5b, 6, 7,7a,8,9,10,ll,lla,llb,12,13,l 3 a -octa decahydro-2H-cyclopenta[a ]chrysen-9-yl acetate:

To a stirred solution of ((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a -octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate (step 4, 145 g, 268.32 mmol, 1.0 eq) in toluene (190 mL) : ethanol (190 mL) (1: 1) was added potassium hydroxide (15.0 g, 268.32 mmol, 1.0 eq). The reaction mixture was stirred at room temperature for 45 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with aqueous IN HC1 and evaporated to dryness. The obtained residue was taken up in water and a small amount of acetone and stirred at room temperature for 1 hour. The precipitates formed were collected by filtration, washed with water and dried in vacuo to obtain the title compound (105 g, yield: 78.46%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 4.49 (dd, = 10.2, 6.0 Hz, 1H), 3.72 (d, = 10.5 Hz, 1H), 3.67 (d, = 10.5 Hz, 1H), 3.25- 3.14 (m, 1H), 2.78 (dd, = 12.6, 3.3 Hz, 1H), 2.44 (d, = 18.6 Hz, 1H), 2.05 (s, 3H), 2.0- 1.65 (m, 8H), 1.63-1.25 (m, 8H), 1.24-1.17 (m, 7H), 1.13 (s, 3H), 1.09-0.99 (m, 1H), 0.94 (s, 3H), 0.92 (s, 3H), 0.86 (s, 3H), 0.85 (s, 3H), 0.80 (m, 1H); ESI-MS: m/z 499.45 (M+H)⁺. Step 6: Synthesis of (3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl-5a,5b, 8,8, 11 a-pentamethyl-2-oxo-2, 3,4,5, 5a,5b,6,7, 7a,8,9, 10, 11,11 a,l lb, 12, 13,13a-octadecahydro- 3aH-cyclopenta[a ] chrysene-3a-carboxylic acid:

To a stirred solution of (3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(hydroxymethyl)- l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (step 5, 100.0 g, 200.5 mmol, 1.0 eq) in THF (1000 mL) at room temperature was added TEMPO (3.12 g, 20.0 mmol, 0.1 eq), stirred for 10 minutes, then NaH₂P0₄ (72.18 g, 601.50 mmol, 3.0 eq) dissolved in water (600 mL) was added followed by NaHC0₃ (33.684 g, 401.0 mmol, 2.0 eq) was added and stirred for 10 minutes. NaC10₂ (54.13 g, 601.5 mmol, 3.0 eq) was added slowly portion wise over a period of 30 minutes and stirred for another 10 minutes. The reaction mixture was cooled to 0-5 °C and added 10% sodium hypochlorite solution (150 mL) slowly over a period of 30 minutes and stirred at the same temperature for another 30 minutes. The reaction mixture was allowed to stir at room temperature for 3 hours. After completion of the reaction (monitored by TLC), IN HCl solution (400 mL) was added and stirred at 0 °C for 30 minutes. Ethyl acetate (1050 mL) was added to the reaction mixture and stirred for 30 minutes. Organic layer was separated and the aqueous layer was extracted with ethyl acetate (2x600 mL). The combined organic layer was washed with water (500 mL) and brine solution (500 mL). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was triturated with heptane (420 mL) and stirred for 3 hours at room temperature. The precipitates were filtered, washed with heptane (100 mL) and dried under vacuum to obtain the title compound (77.0 g, yield: 74.9%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 4.49 (dd, J = 10.5, 6.0 Hz, 1H), 3.27-3.15 (m, 1H), 2.78-2.71 (m, 1H), 2.59 (d, = 18.6 Hz, 1H), 2.49-2.43 (m, 1H), 2.19 (d, = 18.6 Hz, 1H), 2.05 (s, 3H), 2.02-1.03 (m, 22H), 1.05 (s, 3H), 0.94 (s, 3H), 0.91 (s, 3H), 0.85 (s, 3H), 0.84 (s, 3H), 0.80 (m, 1H); ESI- MS: m/z 513.50 (M+H)⁺.

Step 7: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-l-isopropyl-3a-((((4-methoxy benzyl)oxy)carbonyl)amino)-5a,5b,8,8,lla-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10, 11 ,11 a,l lb, 12,13,13a-octadecahydro-2H-cyclopenta[a] ' chrysen-9-yl acetate:

To a stirred solution of (3atf,5atf,5btf,7atf,9S,l la7 lb7 3aS)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a -octadecahydro-3aH-cyclopenta[a]chrysene-3a-carboxylic acid (step 6, 75.0 g, 146.27 mmol, 1.0 eq) in toluene (1500 mL) at 0 °C was added triethyl amine (50.8 mL, 365.68 mmol, 2.5 eq), followed by diphenylphosphonic azide (69.3 mL, 190.158 mmol, 1.3 eq). After 30 minutes stirring at room temperature, the solution was heated to reflux for about 100 minutes. After which it was converted completely to the isocyanate by TLC, /?-methoxybenzyl alcohol (26.274 g, 190.158 mmol, 1.3 eq) was added and reflux was continued for 4 hours. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with ice cooled water (1500 mL) and extracted with DCM (3x550 mL). The combined organic extracts were washed with brine solution (500 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The obtained residue was stirred with methanol (150 mL) at room temperature for 20 minutes. The precipitates formed were collected by filtration and dried under vacuum to obtain the title compound (69.1 g, yield: 73%) as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.32-7.20 (m, 2H), 6.88 (d, = 8.4 Hz, 2H), 4.98 (s, 2H), 4.83 (s, 1H), 4.48 (dd, / = 10.2, 6.0 Hz, 1H), 3.80 (s, 3H), 3.22- 3.0 (m, 1H), 2.82-2.58 (m, 2H), 2.35-2.20 (m, 2H), 2.05 (s, 3H), 1.98-1.58 (m, 8H), 1.58-1.32 (m, 6H), 1.28-1.12 (m, 8H), 1.07 (s, 3H), 0.91 (s, 6H), 0.87-0.78 (m, 7H); ESI-MS: m/z 670.61 (M+Na)⁺.

Step 8: Synthesis of (3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-amino-l-isopropyl-5a,5b, 8,8,lla-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadeca hydro-2H-cyclopenta[a] chrysen- -yl acetate:

To a stirred solution of (3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-((((4- methoxybenzyl)oxy)carbonyl)amino)-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (step 7, 69.0 g, 106.49 mmol, 1.0 eq) in DCM (690 mL) at 0 °C was added TFA (138 mlL). The reaction mixture was allowed to stir at room temperature for 3 hours. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, water (500 mL) was added, cooled to 0 °C, pH adjusted to 8.0 with saturated NaHC0₃ solution and extracted with DCM (3x600 mL). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The obtained residue was stirred with diethyl ether (100 mL) and hexane (5 mL) at room temperature for 10 minutes. The precipitates formed were collected by filtration and dried under vacuum to obtain the title compound (45.0 g, yield: 87.37%) as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 4.48 (dd, / = 10.2, 6.0 Hz, 1H), 3.20-3.05 (m, 1H), 2.29 (m, 2H), 2.05 (s, 3H), 1.98-1.82 (m, 3H), 1.80-1.48 (m, 8H), 1.45-1.29 (m, 4H), 1.29-1.0 (m, 12H), 0.92 (s, 3H), 0.90 (s, 3H), 0.87-0.78 (m, 7H).

Step 9: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-((tert-butoxycarbonyl) amino)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,lla-pentamethyl-2-oxo-3,3a,4,5,5a, 5b,6, 7,7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate:

To a stirred solution of 2-((ieri-butoxycarbonyl)amino)-2-methylpropanoic acid (Intermediate 1-step 1, 22.687 g, 111.63 mmol, 1.2 eq) in DMF (675 mL) at 0 °C was added TEA (64.65 mL, 465.12 mmol, 5.0 eq) followed by HBTU (52.918 g, 139.53 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 30 minutes, then { aR,5&R,5bR,l&R,9S,\ \&R,\ lb7?,13aS)-3a-amino-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[(3] chrysen-9-yl acetate (step 8, 45.0 g, 93.025 mmol, 1.0 eq) was added and stirred at same temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (800 mL) and stirred at 0 °C for 30 minutes. The precipitates formed were collected by filtration, washed with water (250 mL) and dried under vacuum to obtain the title compound (54.08 g, yield: 87%) as a white solid, used in the next step without further purification. 1H NMR (300 MHz, CDC1₃): δ ppm 4.84 (brs, 1H), 4.49 (dd, = 10.5, 5.7 Hz, 1H), 3.20-3.08 (m, 1H), 2.88-2.80 (m, 1H), 2.68 (d, = 18.6 Hz, 1H), 2.39-2.32 (m, 1H), 2.27 (d, = 18.6 Hz, 1H), 2.05 (s, 3H), 1.98-1.82 (m, 3H), 1.81-1.57 (m, 7H), 1.49 (s, 3H), 1.47 (s, 3H), 1.42 (s, 9H), 1.39-1.34 (m, 3H), 1.29-1.17 (m, 8H), 1.17 (s, 3H), 1.10-1.01 (m, 1H), 0.93 (s, 3H), 0.92 (s, 3H), 0.88-0.79 (m, 7H); ESI-MS: m/z 691.63 (M+Na)⁺.

Step 10: Synthesis of tert-butyl (l-(((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-9-hydroxy-l- isopropyl-5a,5b,8,8,lla-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,

13,13a-octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)amino)-2-methyl-l-oxopropan-2- yl)carbamate:

To a stirred solution of (3atf,5atf,5btf,7atf,9S,l la lW 3aS)-3a-(2-((te/ - butoxycarbonyl)amino)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[(3] chrysen-9-yl acetate (step 9, 54.0 g, 80.78 mmol, 1.0 eq) in MeOH (216 niL), THF (108 niL) and water (54 niL) at 0 °C was added NaOH (32.315 g, 807.89 mmol, 10.0 eq). The reaction mixture was removed from the ice bath and was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the organic phase was evaporated under reduced pressure, diluted with water (300 mL) and extracted with DCM (3x600 mL). The combined organic extracts were washed with water (500 mL), brine solution (500 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-4% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (43.0 g, yield: 85%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.0 (brs, 1H), 4.83 (brs, 1H), 3.26-3.08 (m, 2H), 2.88-2.81 (m, 1H), 2.68 (d, = 18.6 Hz, 1H), 2.38-2.31 (m, 1H), 2.27 (d, = 18.6 Hz, 1H), 1.97-1.83 (m, 2H), 1.80-1.63 (m, 2H), 1.62-1.55 (m, 6H), 1.49 (s, 3H), 1.47 (s, 3H), 1.42 (s, 9H), 1.39-1.25 (m, 5H), 1.24-1.17 (m, 6H), 1.14 (s, 3H), 1.10-1.02 (m, 1H), 0.97 (s, 3H), 0.94 (s, 3H), 0.89 (s, 3H), 0.77 (s, 3H), 0.75-0.68 (m, 1H); ESI-MS: m/z 649.66 (M+Na)⁺.

Step 11: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-((tert- butoxycarbonyl)amino)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,lla-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6, 7,7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl) (lR,3S)- -dimethylcyclobutane-l,3-dicarboxylate:

stirred solution of tert-butyl (l-(((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9- hydroxy-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la, l lb,12,13,13a-octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)amino)-2-methyl-l-oxo propan-2-yl)carbamate (step 10, 43.0 g, 68.589 mmol, 1.0 eq) in DCM (430 mL) at 0 °C under nitrogen atmosphere was added (lS,3R)-3-((benzyloxy)carbonyl)-2,2- dimethylcyclobutane-l-carboxylic acid (prepared as described in WO 2011/007230 A2, 26.99 g, 102.88 mmol, 1.5 eq) followed by EDCI (53.238, 342.945 mmol, 5.0 eq) and DMAP (25.103 g, 205.765 mmol, 3.0 eq). The mixture was removed from the ice bath and was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (500 mL) and extracted with DCM (3x500 mL). The combined organic extracts were washed with water (500 mL) and brine solution (300 mL). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-4% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (43.0 g, yield: 71.96%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.35 (m, 5H), 7.01 (brs, 1H), 5.15, 5.09 (ABq, JAB = 12.6 Hz, 2H), 4.83 (brs, 1H), 4.45 (dd, = 11.4, 4.5 Hz, 1H), 3.20-3.08 (m, 1H), 2.88-2.58 (m, 5H), 2.40-2.33 (m, 1H), 2.27 (d, = 18.6 Hz, 1H), 2.09-2.02 (m, 1H), 2.0-1.82 (m, 3H), 1.81-1.70 (m, 2H), 1.65-1.54 (m, 5H), 1.49 (s, 3H), 1.46 (s, 3H), 1.42 (s, 9H), 1.40-1.30 (m, 4H), 1.34 (s, 3H), 1.30-1.17 (m, 7H), 1.14 (s, 3H), 1.11-1.0 (m, 1H), 0.96 (s, 3H), 0.93 (s, 3H), 0.91 (s, 3H), 0.86 (s, 3H), 0.85 (s, 3H), 0.79 (m, 1H); ESI-MS: m/z 894.05 (M+Na)⁺.

Step 12: Synthesis of l-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-amino-2-methyl propanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-3,3a,4, 5, 5a,5b,6,7, 7a,8,9, 10,11, lla,llb,12,13,l 3a-octadecahydro-2H-cyclopenta[a ]chrysen-9-yl ) 3 -benzyl (lS,3R)-2,2- dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((tert-butoxycarbonyl)amino)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 11, 43.0 g, 49.35 mmol, 1.0 eq) in DCM (360 mL) at 0 °C was added trifluoroacetic acid (70 mL). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, water (150 mL) was added, cooled to 0 °C, pH adjusted to 8.0 with saturated sodium bicarbonate solution and extracted with DCM (3x500 mL). The combined organic extracts were washed with water (300 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was triturated with methanol (150 mL) and stirred at room temperature for 1 hour. The precipitates formed were collected by filtration, washed with methanol and dried under vacuum to obtain the title compound (26.0 g, yield: 68.3%) as an off- white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.98 (brs, 1H), 7.35 (m, 5H), 5.15, 5.09 (ABq, J_AB = 12.6 Hz, 2H), 4.45 (dd, = 11.4, 4.8 Hz, 1H), 3.20-3.09 (m, 1H), 2.87-2.61 (m, 5H), 2.43-2.35 (m, 1H), 2.30 (d, = 18.6 Hz, 1H), 2.10-2.02 (m, 1H), 1.99-1.85 (m, 2H), 1.84-1.67 (m, 2H), 1.65-1.60 (m, 2H), 1.53-1.40 (m, 4H), 1.40-1.32 (m, 12H), 1.27-1.15 (m, 8H), 1.12 (s, 3H), 1.09-1.01 (m, 1H), 0.96 (s, 3H), 0.94 (s, 3H), 0.91 (s, 3H), 0.87-0.78 (m, 7H); ESI-MS: m/z 771.66 (M+H)⁺.

Intermediate 2: Preparation of 4-(2-methoxyethoxy)benzoic acid:

Step 1: Synthesis of 2-methoxyethyl 4-methylbenzenesulfonate: To a stirred solution of 2-methoxyethan-l-ol (2.0 g, 26.28 mmol, 1.0 eq) in DCM (30 mL) at 0 °C was added TEA (14.6 mL, 105.12 mmol, 4.0 eq) followed by para- toluenesulfonyl chloride (5.99 g, 31.53 mmol, 1.2 eq). The reaction mixture was changed to room temperature and stirred for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with water (50 mL) and brine solution (20 mL). The organic layer was dried over Na₂S0₄, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 40% ethyl acetate in hexane as an eluent to obtain the title compound (4.3 g, yield: 71.6%) as a liquid. 1H NMR (300 MHz, CDCI3): δ ppm 7.80 (d, = 8.4 Hz, 2H), 7.35 (d, = 8.1 Hz, 2H), 4.15 (t, = 4.8 Hz, 2H), 3.57 (t, = 4.8 Hz, 2H), 3.30 (s, 3H), 2.44 (s, 3H); ESI-MS: m/z 252.96 (M+Na)⁺

Step 2: Synthesis of methyl 4-(2-methoxyethoxy)benzoate:

To a stirred solution of methyl 4-hydroxybenzoate (1.0 g, 6.572 mmol, 1.0 eq) in acetone (15 mL) was added K₂CO₃ (4.53 g, 32.86 mmol, 5.0 eq) followed by 2-methoxyethyl 4-methylbenzenesulfonate (step 1, 3.0 g, 13.14 mmol, 2.0 eq) and tetra-n-butylammonium bromide (0.423 g, 1.314 mmol, 0.2 eq). The reaction mixture was heated to reflux for 6 hours. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (50 mL) and extracted with ethyl acetate (3x50 mL). The combined organic extracts were washed with water (50 mL) and brine solution (10 mL). The organic layer was dried over Na₂S0₄, filtered and evaporated under reduced pressure to obtain the title compound (1.5 g) as a colourless liquid, used for the next step without further purification. 1H NMR (300 MHz, CDCI₃): δ ppm 7.98 (d, = 8.7 Hz, 2H), 6.94 (d, = 8.7 Hz, 2H), 4.18-4.14 (m, 2H), 3.79-3.74 (m, 2H), 3.88 (s, 3H), 3.45 (s, 3H).

Step 3: Synthesis of 4-(2-methoxyethoxy)benzoic acid:

To a stirred solution of methyl 4-(2-methoxyethoxy)benzoate (step 2, 1.5 g, 7.142 mmol, 1.0 eq) in MeOH (10 mL) at 0 °C was added aqueous IN NaOH solution (57.1 mL, 57.142 mmol, 8.0 eq). The reaction mixture was allowed to stir at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, neutralized with IN HCl and evaporated under reduced pressure to obtain the title compound (1.0 g) as an off-white solid, used in next step without further purification. 1H NMR (300 MHz, DMSO-d₆): δ ppm 7.88 (d, = 8.7 Hz, 2H), 7.03 (d, = 8.7 Hz, 2H), 4.16 (t, = 4.5 Hz, 2H), 3.67 (t, = 4.5 Hz, 2H), 3.30 (s, 3H).

Intermediate 3: Preparation of 2-methyl-lH-benzordlimidazole-5-carboxylic acid:

Step 1: Synthesis of methyl 2-methyl-lH-benzo[d]imidazole-5-carboxylate:

To a stirred solution of methyl 3,4-diaminobenzoate (1.0 g, 6.017 mmol, 1.0 eq) in acetonitrile (10 mL) was added methyl 3-oxobutanoate (1.048 g, 9.026 mmol, 1.5 eq) and para-toluenesulfonic acid monohydrate (0.572 g, 3.008 mmol, 0.5 eq). The reaction mixture was heated at 80 °C for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure, diluted with water (10 mL), neutralized with saturated sodium bicarbonate solution and extracted with DCM (2x100 mL). The combined organic extracts were dried over Na₂S0₄, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0- 5% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.500 g, yield: 43.8%) as a brown colour solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.27 (s, 1H), 7.95 (dd, J = 8.4, 1.5 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 3.93 (s, 3H), 2.67 (s, 3H); ESI-MS: m/z 191.0 (M+H)⁺.

Step 2: Synthesis of2-methyl-lH-benzo[d]imidazole-5-carboxylic acid:

To a stirred solution of methyl 2-methyl-lH-benzo[d]imidazole-5-carboxylate (step 1, 0.500 g, 2.628 mmol, 1.0 eq) in MeOH (5 mL) was added aqueous IN NaOH solution (21.0 mL, 21.03 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, neutralized with IN HC1 and evaporated under reduced pressure to obtain the title compound (0.4 g, yield: 86.4%) as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 13.44 (brs, 1H), 8.25 (s, 1H), 8.05 (dd, = 8.4, 1.5 Hz, 1H), 7.82 (d, = 8.4 Hz, 1H), 2.80 (s, 3H); ESI-MS: m/z 176.95 (M+H)⁺.

Intermediate 4: Preparation of 6-morpholinonicotinic acid:

To a stirred solution of methyl 6-morpholinonicotinate (2.0 g, 9.00 mmol, 1.0 eq) in MeOH (20 mL) at 0 °C was added aqueous IN NaOH solution (72.0 mL, 72.0 mmol, 8.0 eq). The reaction mixture was allowed to stir at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, neutralized with IN HC1 and evaporated under reduced pressure. To this resulting solid, methanol (40 mL) and dichloromethane (60 mL) were added and stirred at room temperature for 30 minutes. The mixture was filtered and the filtrate was evaporated under reduced pressure to obtain 6- morpholinonicotinic acid (1.5 g, yield: 80%) as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.85 (s, 1H), 8.07 (dd, = 9.0, 2.4 Hz, 1H), 6.60 (d, = 9.0 Hz, 1H), 3.81 (t, = 4.5 Hz, 4H), 3.68 (t, = 4.2 Hz, 4H).

Intermediate 5: Preparation of 3-methyl- -pyrazole-5-carboxylic acid:

To a stirred solution of ethyl 3-methyl-lH-pyrazole-5-carboxylate (1.0 g, 6.486 mmol, 1.0 eq) in ethanol (10 mL) was added aqueous IN NaOH solution (51.89 mL, 51.89 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, neutralized with IN HC1 and evaporated under reduced pressure. The resulting mixture was co-distilled with acetonitrile (50 mL) to obtain the title compound (1.0 g) as a solid, used in next step without further purification. 1H NMR (300 MHz, CDC1₃): δ ppm 6.50 (s, 1H), 2.31 (s, 3H).

Intermediate 6: Preparation of 3-methyl-lH-pyrazole-5-carboxylic acid:

Step 1: Synthesis of methyl 6-(l ,1 - )nicotinate:

To a stirred solution of methyl 6-chloronicotinate (3.5 g, 20.396 mmol, 1.0 eq) in DMF (60 mL) was added thiomorpholine 1,1-dioxide (4.135 g, 30.594 mmol, 1.5 eq) followed by sodium iodide (3.057 g, 20.396 mmol, 1.0 eq) and DIPEA (14.5 mL, 81.584 mmol, 4.0 eq). The reaction mixture was heated at 120 to 130 °C for 22 hours. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2x50 mL). The combined organic extracts were washed with water (2x100 mL) and brine solution (50 mL). The organic layer was dried over Na₂S0₄, filtered and evaporated under reduced pressure. The crude compound was purified by silica gel chromatography by using 40% ethyl acetate in hexane as an eluent to obtain the title compound (1.0 g, yield: 18.14%) as a colourless solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.83 (d, = 1.5 Hz, 1H), 8.13 (dd, / = 9.0, 2.1 Hz, 1H), 6.73 (d, J = 9.0 Hz, 1H), 4.26 (t, J = 4.8 Hz, 4H), 3.90 (s, 3H), 3.07 (t, J = 4.8 Hz, 4H); ESI-MS: m/z 292.87 (M+Na)⁺.

Step 2: Synthesis of 6-(l ,1 -dioxidothiomorpholino)nicotinic acid:

To a stirred solution of methyl 6-(l,l-dioxidothiomorpholino)nicotinate (step 1, 1.5 g, 5.549 mmol, 1.0 eq) in MeOH (15 mL) and THF (15 mL) at 0 °C was added aqueous IN NaOH solution (44.4 mL, 44.4 mmol, 8.0 eq). The reaction mixture was allowed to stir at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, neutralized with IN HCl and evaporated under reduced pressure. To this resulting solid, 30% methanol in dichloromethane (50 mL) was added and stirred at 60 °C for 1 hour. The mixture was cooled to room temperature, filtered and was washed with 30% methanol in dichloromethane (20 mL). The filtrate was evaporated under reduced pressure to obtain the title compound (0.800 g, yield: 56.3%) as a white solid. 1H NMR (300 MHz, DMSO-d6): δ ppm 8.63 (d, = 1.5 Hz, 1H), 8.06 (dd, = 9.0, 2.1 Hz, 1H), 7.17 (d, J = 9.0 Hz, 1H), 4.18 (m, 4H), 3.20 (m, 4H); ESI-MS: m/z 255.12 (M-H)^~.

Intermediate 7: Preparation of 4- -morpholinopiperidin-l-yl) benzoic acid:

Step 1: Synthesis of tert-butyl 4-hydrox iperidine-l -carboxylate :

To a stirred solution of piperidin-4-ol (10.0 g, 98.86 mmol, 1.0 eq) in 1,4-dioxane (100 mL) at 0 °C was added 2N NaOH solution (50 mL) followed by di-ie/t-butyldicarbonate (34 mL, 148.29 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (100 mL) and extracted with DCM (3x150 mL). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure to obtain the title compound (crude wt: 20.0 g) as a liquid, used in next step without further purification; 1H NMR (300 MHz, CDC1₃): δ ppm 3.90-3.79 (m, 3H), 3.08-2.97 (m, 2H), 1.91-1.75 (m, 4H) 1.45 (s, 9H).

Step 2: Synthesis of tert-butyl 4-oxopiperidine-l -carboxylate:

To a stirred solution of tert-butyl 4-hydroxypiperidine-l-carboxylate (step 1, 8.0 g, 39.74 mmol, 1.0 eq) in DCM (80 mL) was added pyridinium chlorochromate (25.7 g, 119.24 mmol, 3.0 eq) and silica gel (25.7 g). The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (monitored by TLC), the reaction mixture was filtered and the filtrate was diluted with DCM (300 mL), washed with saturated sodium bicarbonate solution. The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 2% methanol in DCM eluent. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound

(7.0 g, yield: 88.49%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 3.72 (t, = 6.3 Hz, 4H), 2.44 (t, = 6.0 Hz, 4H), 1.49 (s, 9H).

Step 3: Synthesis of tert-butyl 4-mor holinopiperidine-l-carboxylate:

To a stirred solution of tert-butyl 4-oxopiperidine-l-carboxylate (step 2, 5.0 g, 25.09 mmol, 1.0 eq) in 1, 2-dichloroethane (50 mL) was added morpholine (2.31 mL, 26.34 mmol, 1.05 eq) followed by acetic acid (1.806 g, 30.108 mmol, 1.2 eq). The reaction mixture was stirred at room temperature for 10 minutes. Sodium triacetoxyborohydride (10.63 g, 50.18 mmol, 2.0 eq) was added and stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with DCM (50 mL) then washed with 2N sodium hydroxide (20 mL) followed by water (50 mL). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 2% methanol in DCM eluent. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (4.0 g, yield: 58.99%) as a colourless solid. 1H

NMR (300 MHz, CDCI3): δ ppm 4.17-4.09 (m, 2H), 3.72 (t, = 4.5 Hz, 4H), 2.71 (t, = 12.3 Hz, 2H), 2.56 (t, = 4.5 Hz, 4H), 2.40-2.28 (m, 1H), 1.87-1.78 (m, 2H), 1.45 (s, 9H), 1.42- 1.23 (m, 2H); ESI-MS: m/z 271.12 (M+H)⁺.

Step 4: Synthesis of 4-(piperidin-4-yl)morpholine:

To a stirred solution of tert-butyl 4-morpholinopiperidine-l-carboxylate (step 3, 4.0 g, 14.848 mmol, 1.0 eq) in DCM (40 mL) was added TFA (20 mL). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure then pH adjusted to 8.0 with saturated NaHC0₃ solution and extracted with 10% methanol in DCM (2x50 mL). The combined organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure to obtain the title compound (3.0 g) as a solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 3.55 (t, = 4.5 Hz, 4H), 3.02-2.94 (m, 2H), 2.44-2.39 (m, 4H), 2.26-2.12 (m, 1H), 2.07 (m, 2H), 1.73-1.64 (m, 2H), 1.32-1.16 (m, 2H); ESI-MS: m/z 171.03 (M+H)⁺.

Step 5: Synthesis of Methyl 4-(4-morpholinopiperidin-l -yl)benzoate :

To a stirred solution of methyl 4-bromobenzoate (4.54 g, 21.14 mmol, 1.2 eq) in toluene (30 mL) was added 4-(piperidin-4-yl)morpholine (step 4, 3.0 g, 17.62 mmol, 1.0 eq) and Cs₂C0₃ (17.2 g, 52.86 mmol, 3.0 eq). The reaction mixture was purged with nitrogen for 10 minutes. Next, palladium acetate (0.039 g, 0.176 mmol, 0.01 eq) and BINAP (0.164 g, 0.264 mmol, 0.015 eq) were added and the reaction mixture was degassed for 30 minutes and heated at 100 °C for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was allowed to cool to room temperature, filtered through celite pad and was washed with ethyl acetate (50 mL). The organic layer was washed with saturated sodium bicarbonate solution and followed by water (50 mL). The organic layer was dried over Na₂S0_4i filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 1% methanol in dichloromethane as an eluent to obtain the title compound (1 g, yield: 18.65%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.90 (d, = 9.0 Hz, 2H), 6.86 (d, = 9.0 Hz, 2H), 3.97-3.86 (m, 2H), 3.85 (s, 3H), 3.73 (t, = 4.5 Hz, 4H), 2.92-2.81 (m, 2H), 2.57 (t, = 4.5 Hz, 4H), 2.47-2.35 (m, 1H), 2.10-1.90 (m, 2H), 1.70-1.52 (m, 2H); ESI-MS: m/z 305.11 (M+H)⁺.

Step 6: Synthesis of 4-(4-morpholinopiperidin-l -yl) benzoic acid:

To a stirred solution of methyl 4-(4-morpholinopiperidin-l-yl) benzoate (step 5, 1.0 g,

3.280 mmol, 1.0 eq) in MeOH (10 mL) was added aqueous IN NaOH solution (26.28 mL, 26.28 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HC1 and evaporated under reduced pressure. The crude solid was co-distilled with CH₃CN (2x50 mL) and dried under vacuum at 60 °C for 3 hours to obtain the title compound (1.0 g) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.84 (d, = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 3.94-3.86 (m, 2H), 3.75-3.68 (m, 4H), 2.83-2.72 (m, 2H), 2.67-2.60 (m, 4H), 2.45-2.35 (m, 1H), 2.07-1.97 (m, 2H), 1.67-1.52 (m, 2H); ESI-MS: m/z 290.94 (M+H)⁺.

Intermediate 8: Preparation of 4-((4-hydroxypiperidin-l-yl)methyl)benzoic acid:

Synthesis of methyl 4-((4-hydroxypiperidin-l-yl)methyl)benzoate:

To a stirred solution of methyl 4-(bromomethyl)benzoate (4.0 g, 17.46 mmol, 1.0 eq) in CH₃CN (80 mL) was added Cs₂C0₃ (17.06 g, 52.38 mmol, 3.0 eq). The reaction mixture was stirred at room temperature for 1 hour, piperidin-4-ol (3.53 g, 34.92 mmol, 2.0 eq) was added and heated to reflux for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through celite pad and was washed with ethyl acetate (100 mL). The organic layer was washed with water (100 mL), dried over Na₂S0_4i filtered and evaporated under reduced pressure to obtain the title compound (4.0 g, yield: 91.9%) as a yellow oil. 1H NMR (300 MHz, CDC1₃): δ ppm 7.98 (d, = 8.1 Hz, 2H), 7.39 (d, = 8.1 Hz, 2H), 3.91 (s, 3H), 3.78-3.66 (m, 1H), 3.54 (s, 2H), 2.77- 2.70 (m, 2H), 2.16 (t, = 9.6 Hz, 2H), 1.95-1.85 (m, 2H), 1.69-1.50 (m, 2H); ESI-MS: m/z 250.03 (M+H)⁺.

Step 2: Synthesis of 4-((4-hydroxypiperidin-l -yl)methyl)benzoic acid:

To a stirred solution of methyl 4-((4-hydroxypiperidin-l-yl)methyl)benzoate (step 1, 4.0 g, 16.044 mmol, 1.0 eq) in MeOH (40 mL) was added aqueous IN NaOH solution (128.35 mL, 128.35 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HC1 (28 mL) and evaporated under reduced pressure. The residue was co-distilled with acetonitrile (100 ml) to obtain the title compound (3 g) as a white solid; ESI- MS: m/z 236.05 (M+H)⁺.

Intermediate 9: Preparation of 4-(morpholinomethyl)benzoic acid:

Step 1: Synthesis of methyl 4-(morpholinomethyl)benzoate:

To a stirred solution of methyl 4-(bromomethyl)benzoate (4.0 g, 17.46 mmol, 1.0 eq) in CH₃CN (100 mL) was added Cs₂C0₃ (17.06 g, 52.38 mmol, 3.0 eq). The reaction mixture was stirred at room temperature for 1 hour, morpholine (3.04 g, 34.92 mmol, 2.0 eq) was added and refluxed for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through celite pad and was washed with ethyl acetate (200 mL). The organic layer was washed with water (100 mL), dried over Na₂S0_4i filtered and evaporated under reduced pressure to obtain the title compound (4.0 g, yield: 97.37%) as a yellow oil. 1H NMR (300 MHz, CDC1₃): δ ppm 7.99 (d, = 8.1 Hz, 2H), 7.41 (d, = 7.8 Hz, 2H), 3.90 (s, 3H), 3.70 (t, = 4.5 Hz, 4H), 3.53 (s, 2H), 2.44 (t, = 4.5 Hz, 4H); ESI-MS: m/z 235.99 (M+H)⁺.

Step 2: Synthesis of 4-(morpholinomethyl)benzoic acid:

To a stirred solution of methyl 4-(morpholinomethyl)benzoate (step 1, 4.0 g, 17.00 mmol, 1.0 eq) in MeOH (40 mL) at 0 °C was added aqueous IN NaOH solution (136.0 mL, 136.0 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, neutralized with IN HC1 and evaporated under reduced pressure. To the resulting solid, methanol (40 mL) and dichloromethane (60 mL) were added and stirred at room temperature for 30 minutes. The mixture was filtered and the filtrate was evaporated under reduced pressure. The above procedure was repeated twice and the obtained solid (3.0 g, yield: 79.57%) was used as such for next step without further purification. 1H NMR (300 MHz, CDC1₃): δ ppm 8.04 (d, = 8.1 Hz, 2H), 7.50 (d, = 8.1 Hz, 2H), 3.81 (m, 4H), 3.71 (s, 2H), 2.62 (m, 4H); ESI-MS: m/z 222.01 (M+H)⁺. Intermediate 10: Preparation of (R)-4- tetrahydrofuran-3-yl)oxy)benzoic acid:

Step 1: Synthesis of methyl (R)-4-((tetrah drofuran-3-yl)oxy)benzoate:

To a stirred solution of methyl 4-hydroxybenzoate (5.0 g, 32.862 mmol, 1.0 eq) in

THF (50 mL) was added (S)-tetrahydrofuran-3-ol (5.8 g, 65.724 mmol, 2.0 eq), triphenylphosphine (17.23 g, 65.724 mmol, 2.0 eq) and diethylazodicarboxylate (15.45 g, 88.727 mmol, 2.7 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with ethyl acetate (200 mL) and was washed with water (100 mL). The organic layer was dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-20% ethyl acetate in hexanes gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (5.0 g, yield: 68.49%) as colourless oil. 1H NMR (300 MHz, CDC1₃): δ ppm 7.99 (d, = 8.7 Hz, 2H), 6.88 (d, = 8.7 Hz, 2H), 5.01- 4.96 (m, 1H), 4.23-4.0 (m, 4H), 3.88 (s, 3H), 2.31-2.10 (m, 2H).

Step 2: Synthesis of (R)-4-((tetrahydro uran-3-yl)oxy)benzoic acid:

To a stirred solution of methyl (R)-4-((tetrahydrofuran-3-yl)oxy)benzoate (step 1, 5.0 g, 22.498 mmol, 1.0 eq) in MeOH (50 mL) was added aqueous IN NaOH solution (179.9 mL, 179.9 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, acidified with IN HC1 and stirred at room temperature for 20 minutes. The precipitates collected by filtration were washed with water (50 mL) and co-distilled with acetonitrile (2x100 mL) to obtain the title compound (4.07 g, yield: 86.9%) as a white solid, which is used as such for next step without further purification. 1H NMR (300 MHz, CD₃OD): δ ppm

7.97 (d, = 9.0 Hz, 2H), 6.97 (d, = 8.7 Hz, 2H), 5.14-5.07 (m, 1H), 4.02-3.83 (m, 4H), 2.37-2.22 (m, 1H), 2.16-2.10 (m, 1H); ESI-MS: m/z 207.13 (M-H)^~. Intermediate 11: Preparation of 4-(2-morpholinoethoxy)benzoic acid:

Synthesis of 2-morpholinoetha -l -ol:

To a stirred solution of 2-bromoethan-l-ol (43.0 g, 344.35 mmol, 6.0 eq) in acetonitrile (75 mL) was added cesium carbonate (56.0 g, 172.17 mmol, 3.0 eq). The reaction mixture was stirred at room temperature for 1 hour, then added morpholine (5.0 g, 57.392 mmol, 1.0 eq). The reaction mixture was refluxed for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was allowed to cool to room temperature, filtered through celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography by using 3-10% methanol in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (3.0 g, yield: 39.89%) as a colourless oil. 1H NMR (300 MHz, CDC1₃): δ ppm 3.72 (t, = 4.8 Hz, 4H), 3.63 (t, = 5.1 Hz, 2H), 2.58- 2.49 (m, 6H).

Step 2: Synthesis of 4-(2-chloroethyl) morpholine:

To a stirred solution of 2-morpholinoethan-l -ol (step 1, 3.0 g, 22.869 mmol, 1.0 eq) in DCM (45 mL) at 0 °C was added four drops of DMF and thionyl chloride (9.17 mL, 125.78 mmol, 5.5 eq). The reaction mixture was warmed to room temperature and heated at 40 °C for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (100 mL) and extracted with DCM (3x50 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (200 mL) and water (100 mL). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 2-3% methanol in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.5 g, yield: 43.85%) as a colourless oil. 1H NMR (300 MHz, CDC1₃): δ ppm

3.72 (t, = 4.5 Hz, 4H), 3.59 (t, = 6.9 Hz, 2H), 2.72 (t, = 6.9 Hz, 2H), 2.51 (t,

4H); ESI-MS: m/z 150.0 (M+H)⁺. Synthesis of methyl 4-(2-m rpholinoethoxy)benzoate:

To a stirred solution of methyl 4-hydroxybenzoate (1.0 g, 6.572 mmol, 1.0 eq) in acetone (50 mL) was added K₂C0₃ (4.54 g, 32.86 mmol, 5.0 eq), 4-(2- chloroethyl)morpholine (step 2, 1.47 g, 9.858 mmol, 1.5 eq) and tetra-n-butylammonium bromide (0.423 g, 1.314 mmol, 0.2 eq). The reaction mixture was refluxed for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (50 mL) and extracted with ethyl acetate (2x100 mL). The combined organic extracts were washed with water (50 mL), brine solution (20 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 70-80% ethyl acetate in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.0 g, yield: 57.37%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.99 (d, = 8.7 Hz, 2H), 6.92 (d, = 9.0 Hz, 2H), 4.16 (t, = 5.7 Hz, 2H), 3.88 (s, 3H), 3.74 (t, = 4.5 Hz, 4H), 2.82 (t, = 5.4 Hz, 2H), 2.59 (t, = 4.5 Hz, 4H); ESI-MS: m/z 266.23 (M+H)⁺.

Step 4: Synthesis of 4-(2-morpholinoethoxy)benzoic acid:

To a stirred solution of methyl 4-(2-morpholinoethoxy)benzoate (step 3, 1.0 g, 3.769 mmol, 1.0 eq) in MeOH (10 mL) was added aqueous IN NaOH solution (30.15 mL, 30.15 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, acidified with IN HC1 and evaporated under reduced pressure. The crude compound was co- distilled with acetonitrile (20 mL) to obtain the title compound (crude weight: 1.0 g) as a white solid, used in next step without further purification; 1H NMR (300 MHz, DMSO-d₆): δ ppm 11.98 (brs, 1H), 7.92 (d, = 8.4 Hz, 2H), 7.09 (d, = 8.7 Hz, 2H), 4.55 (t, = 4.2 Hz, 2H), 3.93-3.83 (m, 4H), 3.61-3.35 (m, 4H), 3.21 (m, 2H); ESI-MS: m/z 252.07 (M+H)⁺. Intermediate 12: Preparation of 4-((4-methylpiperazin-l-yl)methyl)benzoic acid:

Step 1: Synthesis of methyl 4-((4-methylpiperazin-l-yl)methyl)benzoate:

To a stirred solution of methyl 4-(bromomethyl)benzoate (4.0 g, 17.46 mmol, 1.0 eq) in CH₃CN (40 mL) was added Cs₂C0₃ (17.06 g, 52.38 mmol, 3.0 eq). The reaction mixture was stirred at room temperature for 1 hour, 1-methylpiperazine (3.49 g, 34.92 mmol, 2.0 eq) was added and heated to reflux for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, filtered through celite pad and was washed with ethyl acetate (100 mL). The organic layer was washed with water (100 mL), dried over Na₂S0₄, filtered and evaporated under reduced pressure to obtain the title compound (3.0 g, yield: 69.18%) as yellow oil. 1H NMR (300 MHz, CDC1₃): δ ppm 7.98 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 3.90 (s, 3H), 3.54 (s, 2H), 2.46 (m, 8H), 2.28 (s, 3H); ESI-MS: m/z 249.5 (M+H)⁺.

Step 2: Synthesis of 4-((4-methylpiperazin-l -yl)methyl)benzoic acid:

To a stirred solution of methyl 4-((4-methylpiperazin-l-yl)methyl)benzoate (step 1, 3.0 g, 12.08 mmol, 1.0 eq) in MeOH (30 mL) was added aqueous IN NaOH solution (96.64 mL, 96.64 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HC1 and evaporated under reduced pressure to obtain the title compound (3 g) as a white solid. ESI-MS: m/z 235.34 (M+H)⁺.

Intermediate 13: Preparation of (S)-4- tetrahvdrofuran-3-yl)oxy)benzoic acid:

Step 1: Synthesis of methyl (S)-4-((tetrahydrofuran-3-yl)oxy)benzoate:

To a stirred solution of methyl 4-hydroxybenzoate (2.0 g, 13.14 mmol, 1.0 eq) in THF (20 mL) was added (R)-tetrahydrofuran-3-ol (2.32 g, 26.28 mmol, 2.0 eq), triphenylphosphine (6.89 g, 26.28 mmol, 2.0 eq) and diethylazodicarboxylate (6.18 g, 35.49 mmol, 2.7 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with ethyl acetate (200 mL) and was washed with water (100 mL). The organic layer was dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-20% ethyl acetate in hexanes gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (2.0 g, yield: 68.49%) as a colourless oil. 1H NMR (300

MHz, DMSO-d₆): δ ppm 7.91 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 9.0 Hz, 2H), 5.15-5.09 (m, 1H), 4.30-4.0 (m, 2H), 3.95-3.72 (m, 2H), 3.88 (s, 3H), 2.32-2.20 (m, 1H), 2.0-1.99 (m, 1H).

Step 2: Synthesis of (S)-4-((tetrahydro uran-3-yl)oxy)benzoic acid:

To a stirred solution of methyl (S)-4-((tetrahydrofuran-3-yl)oxy)benzoate (step 1, 2.0 g, 8.999 mmol, 1.0 eq) in MeOH (20 mL) was added aqueous IN NaOH solution (71.99 mL, 71.99 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C, acidified with IN HC1 and stirred at room temperature for 20 minutes. The precipitates formed were collected by filtration and washed with water (50 mL). The obtained solid was co-distilled with acetonitrile (2x100 mL) to obtain the title compound (1.0 g, yield: 53.47%) as a white solid. 1H NMR (300 MHz, CD₃OD): δ ppm 7.97 (d, = 8.7 Hz, 2H), 6.96 (d, = 8.7 Hz, 2H), 5.13-5.07 (m, 1H), 4.03-3.83 (m, 4H), 2.37-2.22 (m, 1H), 2.16-2.05 (m, 1H); ESI-MS: m/z 207.13 (M-H)^~.

Intermediate 14: Preparation of 4- -methylpiperazin-l-yl)benzoic acid:

Synthesis of methyl 4-(4-methylpiperazin-l-yl)benzoate:

To a stirred solution of methyl 4-bromobenzoate (7.728 g, 35.938 mmol, 1.2 eq) in toluene (30 mL) was added 1-methylpiperazine (3.0 g, 29.949 mmol, 1.0 eq) and CS₂CO₃ (29.272 g, 89.847 mmol, 3.0 eq). The reaction mixture was purged with nitrogen for 10 minutes. Next, palladium acetate (0.067 g, 0.299 mmol, 0.01 eq) and BINAP (0.279 g, 0.449 mmol, 0.015 eq) were added and the reaction mixture was degassed for 30 minutes and heated at 100 °C for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was allowed to cool to room temperature, filtered through celite pad and was washed with ethyl acetate (50 mL). The organic layer was washed with saturated sodium bicarbonate solution (25 mL) followed by water (50 mL). The organic layer was dried over Na₂S0_4i filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 1% methanol in dichloromethane as an eluent to obtain the title compound (2.6 g, yield: 37.08%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.92 (d, = 8.7 Hz, 2H), 6.86 (d, = 8.7 Hz, 2H), 3.86 (s, 3H), 3.34 (t, = 4.8 Hz, 4H), 2.55 (t, = 4.8 Hz, 4H), 2.35 (s, 3H); ESI-MS: m/z 235.05 (M+H)⁺.

Step 2: Synthesis of 4-(4-methylpiperazin-l -yl)benzoic acid:

To a stirred solution of methyl 4-(4-methylpiperazin-l-yl)benzoate (step 1, 2.6 g, 11.096 mmol, 1.0 eq) in MeOH (26 mL) was added aqueous IN NaOH solution (88.77 mL, 88.77 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HC1 and evaporated under reduced pressure. The resulting solid was co-distilled with CH₃CN (2x50 mL) and dried under vacuum at 60 °C for 2 hours to obtain the title compound (6.0 g) as an off-white solid. ESI-MS: m/z 221.01 (M+H)⁺.

Intermediate 15: Preparation of 4- -hvdroxypiperidin-l-yl)benzoic acid:

Step 1: Synthesis of tert-butyl 4-acetoxypiperidine-l-carboxylate:

To a stirred solution of tert-butyl 4-hydroxypiperidine-l-carboxylate (step 1 intermediate 7, 6.0 g, 29.81 mmol, 1.0 eq) in DCM (60 mL) at 0 °C was added DMAP (0.76 g, 5.962 mmol, 0.2 eq), triethyl amine (16.75 mL, 119.24 mmol, 4.0 eq) followed by acetic anhydride (9.13 g, 89.43 mmol, 3.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (50 mL) and extracted with DCM (3x30 mL). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-25% ethyl acetate in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (4.0 g, yield: 55.17%) as a colour less liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 4.96-4.85 (m, 1H), 3.76-3.70 (m, 2H), 3.24-3.14 (m, 2H), 2.06 (s, 3H), 1.90-1.79 (m, 2H), 1.64 (m, 2H), 1.44 (s, 9H).

Step 2: Synthesis of piperidin-4-yl acetate:

To a stirred solution of tert-butyl 4-acetoxypiperidine-l-carboxylate (step 1, 4.0 g, 16.44 mmol, 1.0 eq) in DCM (32 mL) was added TFA (8 mL). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, cooled to 0 °C, pH adjusted to 8.0 with saturated NaHC0₃ solution and extracted with 10% methanol in DCM (3x100 mL). The combined organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure to obtain the title compound (2.0 g, yield: 85.1%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 4.97-4.91 (m, 1H), 3.22-3.12 (m, 2H), 3.02-2.87 (m, 2H), 2.07 (s, 3H), 1.92-1.75 (m, 4H); ESI-MS: m/z 144.24 (M+H)⁺

Step 3: Synthesis of methyl 4-(4-acetoxypiperidin-l-yl)benzoate:

To a stirred solution of methyl 4-bromobenzoate (3.6 g, 16.76 mmol, 1.2 eq) in toluene (20 mL) was added piperidin-4-yl acetate (step 2, 2.0 g, 13.967 mmol, 1.0 eq) and Cs₂C0₃ (13.65 g, 41.901 mmol, 3.0 eq). The reaction mixture was purged with nitrogen for 10 minutes. Next, palladium acetate (0.031 g, 0.139 mmol, 0.01 eq) and BINAP (0.130 g, 0.209 mmol, 0.015 eq) were added and the reaction mixture was degassed for 30 minutes and heated at 100 °C for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was allowed to cool to room temperature, filtered through celite pad and was washed with ethyl acetate (50 mL). The organic layer was washed with saturated sodium bicarbonate solution, dried over Na₂S0_4i filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 5% methanol in dichloromethane as an eluent to obtain the title compound (2.0 g, yield: 51.67%) as an off- white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 7.91 (d, = 9.0 Hz, 2H), 6.87 (d, = 9.0 Hz, 2H), 5.02-4.92 (m, 1H), 3.86 (s, 3H), 3.69-3.59 (m, 2H), 3.26-3.15 (m, 2H), 2.07 (s, 3H), 2.04-1.95 (m, 2H), 1.83-1.70 (m, 2H); ESI-MS: m/z 278.33 (M+H)⁺.

Step 4: Synthesis of 4-(4-hydroxypiperidin-l -yl)benzoic acid:

To a stirred solution of methyl 4-(4-acetoxypiperidin-l-yl)benzoate (step 3, 2.0 g, 7.211 mmol, 1.0 eq) in MeOH (20 mL) was added aqueous IN NaOH solution (57.69 mL, 57.69 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HC1 to pH 6.0. The precipitates formed were collected by filtration, washed with hexane (25 mL) and dried under vacuum to obtain the title compound (1.329 g, yield: 83.33%) as an off-white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 12.2 (s, 1H), 7.74 (d, = 9.0 Hz, 2H), 6.94 (d, = 9.0 Hz, 2H), 4.72-4.69 (m, 1H), 3.72-3.66 (m, 2H), 3.06-2.96 (m, 2H), 1.81-1.76 (m, 2H), 1.47-1.33 (m, 2H); ESI-MS: m/z 222.01 (M+H)⁺.

Intermediate 16: Preparation of 4-chloro-2-(2-(lJ-dioxidothiomorpholino)ethoxy)benzoic acid:

Synthesis of methyl 4-chloro-2-hydroxybenzoate:

To a stirred solution of 4-chloro-2-hydroxybenzoic acid (5.0 g, 28.968 mmol, 1.0 eq) in DMF (60 mL) was added Cs₂C0₃ (4.719 g, 14.484 mmol, 0.5 eq) and methyl iodide (4.52 g, 31.864 mmol, 1.1 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (600 mL) and extracted with ethyl acetate (2x100 mL). The combined organic extracts were washed with water (2x200 mL), dried over Na₂S0₄, filtered and evaporated under reduced pressure to obtain the title compound (3.5 g, yield: 64.93%) as a liquid. 1H NMR

(300 MHz, CDC1₃): δ ppm 10.86 (s, 1H), 7.77 (d, = 8.7 Hz, 1H), 7.01 (d, = 2.1 Hz, 1H), 6.87 (dd, = 8.7, 2.1 Hz, 1H), 3.96 (s, 3H).

Step 2: Synthesis of methyl 4-chloro-2-(2-(l ,1 -dioxidothiomorpholino)ethoxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (step 1, 3.0 g, 16.078 mmol, 1.0 eq) in acetone (60 mL) was added K₂CO₃ (11.11 g, 80.39 mmol, 5.0 eq) followed by 4-(2-chloroethyl)thiomorpholine 1,1-dioxide (3.183 g, 16.078 mmol, 1.0 eq) and tetra-n- butylammonium bromide (1.035 g, 3.215 mmol, 0.2 eq). The reaction mixture was heated to reflux for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (200 mL) and extracted with ethyl acetate (2x100 mL). The combined organic extracts were washed with water (100 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-2% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.4 g, yield: 25%) as a liquid. 1H NMR (300 MHz, CDCI3): δ ppm 7.77 (d, = 8.1 Hz, 1H), 7.02-6.93 (m, 2H), 4.14 (t, = 5.1 Hz, 2H), 3.85 (s, 3H), 3.26-3.20 (m, 4H), 3.10-3.01 (m, 6H); ESI-MS: m/z 348.10 (M+H)⁺.

Step 3: Synthesis of 4-chloro-2-(2- l ,1 -dioxidothiomorpholino)ethoxy)benzoic acid:

To a stirred solution of methyl 4-chloro-2-(2-(l,l-dioxidothiomorpholino)ethoxy) benzoate (step 2, 1.4 g, 4.025 mmol, 1.0 eq) in MeOH (14 mL) and THF (14 mL) was added aqueous IN NaOH solution (32.2 mL, 32.20 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was acidified with IN HC1 to pH 4 to 5 and evaporated under reduced pressure. The residue was co-distilled with CH₃CN (20 mL) and dried under vacuum to obtain the solid. The obtained solid was treated with 40% methanol in DCM (100 mL), stirred at room temperature for 30 minutes. The mixture was filtered and the filtrate was evaporated under reduced pressure to obtain the title compound (2.5 g) as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 12.84 (brs, 1H), 7.73 (d, = 8.4 Hz, 1H), 7.29 (d, = 1.2 Hz, 1H), 7.13 (dd, = 8.4, 1.5 Hz, 1H), 4.53 (m, 2H), 4.0-3.35 (m, 10H); ESI-MS: m/z 333.94 (M+H)⁺.

Intermediate 17: Preparation of 4-chloro-2-(2-methoxyethoxy)benzoic acid:

Synthesis of methyl 4-chloro-2- 2-methoxyethoxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.0 g, 10.718 mmol, 1.0 eq) in acetone (50 mL) was added 2-methoxyethyl 4-methylbenzenesulfonate (4.93 g, 21.437 mmol, 2.0 eq) followed by potassium carbonate (7.40 g, 53.59 mmol, 5.0 eq) and TBAB (0.690 g, 2.143 mmol, 0.2 eq). The reaction mixture was refluxed for 6 hours. TLC indicated starting material was consumed and the desired product was observed. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (200 mL) and extracted with ethyl acetate (2x100 mL). The combined organic extracts were washed with water (50 mL), brine solution (20 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 40% ethyl acetate in hexanes as an eluent to obtain the title compound (2.0 g, yield: 76.3%) as a liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.83-7.74 (m, 1H), 6.99-6.95 (m, 2H), 4.17 (t, = 4.8 Hz, 2H), 3.87 (s, 3H), 3.80 (t, = 4.5 Hz, 2H), 3.47 (s, 3H); ESI-MS: m/z 266.93 (M+Na)⁺.

Step 2: Synthesis of4-chloro-2-(2-methox ethoxy)benzoic acid:

To a stirred solution of methyl 4-chloro-2-(2-methoxyethoxy)benzoate (step 1, 2.0 g, 8.174 mmol, 1.0 eq) in MeOH (20 mL) and THF (20 mL) was added aqueous IN NaOH solution (65.39 ml, 65.39 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was acidified with IN HC1 to pH 4 to 5 and evaporated under reduced pressure. The residue was co-distilled with CH₃CN (30 mL) and dried under vacuum to obtain the title compound (2.5 g) as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 12.72 (brs, 1H), 7.63 (d, = 8.4 Hz, 1H), 7.22 (d, = 1.5 Hz, 1H), 7.13-7.04 (m, 1H), 4.19 (t, = 4.5 Hz, 2H), 3.65 (t, = 4.8 Hz, 2H), 3.31 (s, 3H); ESI-MS: m/z 252.89 (M+Na)⁺.

Intermediate 18: Preparation of (R)-4-chloro-2-((tetrahydrofuran-3-yl)oxy)benzoic acid:

Step 1: Synthesis of methyl (R)-4-chloro-2-((tetrahydrofuran-3-yl)oxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.0 g, 10.718 mmol, 1.0 eq) in THF (20 mL) was added (S)-tetrahydrofuran-3-ol (1.88 g, 21.437 mmol, 2.0 eq), triphenylphosphine (5.62 g, 21.437 mmol, 2.0 eq) and diethyl azodicarboxylate (5.04 g, 28.940 mmol, 2.7 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with ethyl acetate (200 mL) and washed with water (100 mL). The organic layer was dried over Na₂S0₄, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-20% ethyl acetate in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.5 g, yield: 54.54%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.76 (d, = 8.4 Hz, 1H), 6.98 (dd, = 8.4, 1.8 Hz, 1H), 6.87 (d, = 1.5 Hz, 1H), 5.0-4.93 (m, 1H), 4.10-3.90 (m, 4H), 3.86 (s, 3H), 2.24-2.17 (m, 2H).

Step 2: Synthesis of (R)-4-chloro-2-((tetrah drofuran-3-yl)oxy)benzoic acid:

To a stirred solution of methyl (R)-4-chloro-2-((tetrahydrofuran-3-yl)oxy)benzoate (step 1, 1.5 g, 5.843 mmol, 1.0 eq) in MeOH (15 mL) was added aqueous IN NaOH solution (46.75 mL, 46.75 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HCl and evaporated under reduced pressure to obtain the title compound

(1.2 g) as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 11.9 (brs, 1H), 7.64 (d, = 8.1 Hz, 1H), 7.20 (d, = 1.5 Hz, 1H), 7.07 (dd, / = 8.4, 1.8 Hz, 1H) 5.16 (t, = 5.1 Hz, 1H), 3.93-3.70 (m, 4H), 2.28-2.13 (m, 1H), 2.02-1.92 (m, 1H); ESI-MS: m/z 265.20 (M+Na)⁺. Intermediate 19: Preparation of 4-chloro-2-(2-morpholinoethoxy)benzoic acid:

Step 1: Synthesis of methyl 4-chloro- -(2-morpholinoethoxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.0 g, 10.718 mmol, 1.0 eq) in acetone (50 mL) was added K₂C0₃ (7.4 g, 53.59 mmol, 5.0 eq) followed by 4-(2- chloroethyl)morpholine (1.6 g, 10.718 mmol, 1.0 eq) and tetra-n-butylammonium bromide (0.690 g, 2.143 mmol, 0.2 eq). The reaction mixture was heated to reflux for 6 hours. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (100 mL) and extracted with ethyl acetate (2x100 mL). The combined organic extracts were washed with water (50 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 80% ethyl acetate in hexane eluent. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.0 g, yield: 31.15%) as a liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.75 (d, = 9.0 Hz, 1H), 6.99-6.95 (m, 2H), 4.20-4.10 (m, 2H), 3.86 (s, 3H), 3.72 (t, J = 4.5 Hz, 4H), 2.85 (t, = 5.4 Hz, 2H), 2.61 (t, = 4.5 Hz, 4H); ESI-MS: m/z 299.99 (M+H)⁺.

Step 2: Synthesis of4-chloro-2-(2-mor holinoethoxy)benzoic acid:

To a stirred solution of methyl 4-chloro-2-(2-morpholinoethoxy)benzoate (step 1, 1.0 g, 3.336 mmol, 1.0 eq) in MeOH (10 mL) was added aqueous IN NaOH solution (26.68 mL, 26.688 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was acidified with IN HC1 to pH 4 to 5 and evaporated under reduced pressure. The residue was co-distilled with CH₃CN (25 mL), washed with n-hexane and dried under vacuum to obtain the title compound (0.6 g) as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 12.0 (brs, 1H), 7.16 (d, = 8.1 Hz, 1H), 6.75 (d, J = 1.2 Hz, 1H), 6.57 (dd, J = 8.4, 1.5 Hz, 1H), 4.05-4.0 (m, 2H), 3.38-3.30 (m, 4H), 3.01-2.95 (m, 2H), 2.83 (m, 4H); ESI-MS: m/z 285.95 (M+H)⁺. Intermediate 20: Preparation of 2-((l-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-4-chloro benzoic acid:

Step 1: Synthesis of tert-butyl 4- tosyloxy)piperidine-l-carboxylate:

To a stirred solution of tert-butyl 4-hydroxypiperidine-l-carboxylate (2.5 g, 12.421 mmol, 1.0 eq) in DCM (25 mL) was added triethyl amine (3.49 mL, 24.842 mmol, 2.0 eq), DMAP (0.151 g, 1.242 mmol, 0.1 eq) followed by /?ara-toluenesulfonyl chloride (2.841 g, 14.905 mmol, 1.2 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (30 mL) and extracted with DCM (3x30 mL). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 3% methanol in DCM as an eluent to obtain the title compound (2.85 g, yield: 64.62%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.80 (d, = 8.4 Hz, 2H), 7.34 (d, = 8.1 Hz, 2H), 4.71-4.64 (m, 1H), 3.64- 3.54 (m, 2H), 3.31-3.18 (m, 2H), 2.45 (s, 3H), 1.83-1.68 (m, 4H), 1.44 (s, 9H); ESI-MS: m/z 378.09 (M+Na)⁺.

Step 2: Synthesis of tert-butyl 4-(5-chloro-2-(methoxycarbonyl)phenoxy)piperidine-l- carboxylate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (1.0 g, 5.35 mmol, 1.0 eq) in acetone (10 mL) was added K₂CO₃ (3.69 g, 26.75 mmol, 5.0 eq) followed by tert-butyl 4- (tosyloxy)piperidine-l-carboxylate (step 1, 2.85 g, 8.039 mmol, 1.5 eq) and tetra-n- butylammonium bromide (0.344 g, 1.07 mmol, 0.2 eq). The reaction mixture was heated to reflux for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (20 mL) and extracted with DCM (3x30 mL). The organic layer was washed with brine solution (20 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-3% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.5 g, yield: 75.68%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.80 (d, J = 8.1 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 6.97 (d, J = 7.2 Hz, 1H), 4.73-4.56 (m, 1H), 3.87 (s, 3H), 3.64-3.50 (m, 3H), 3.30-3.20 (m, 1H), 1.90-1.60 (m, 4H), 1.47 (s, 9H); LC-MS: m/z 370.10 (M+H)⁺.

Step 3: Synthesis of2-((l-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-4-chlorobenzoic acid:

To a stirred solution of tert-butyl 4-(5-chloro-2-(methoxycarbonyl)phenoxy) piperidine-l-carboxylate (step 2, 1.5 g, 4.055 mmol, 1.0 eq) in MeOH (15 mL) was added aqueous IN NaOH solution (32.44 mL, 32.44 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (10 mL), acidified with IN HC1 to pH 5 and extracted with DCM (3x25 mL). The organic layer was separated, dried over Na₂S0₄, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-3% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.901 g, yield: 62.5%) as a colourless liquid.1H NMR (300 MHz, CDCI3): δ ppm 8.13 (d, = 8.4 Hz, 1H), 7.13 (dd, = 8.7, 1.8 Hz, 1H), 7.05 (d, J = 1.5 Hz, 1H), 4.79-4.70 (m, 1H), 3.90-3.79 (m, 2H), 3.37-3.25 (m, 2H), 2.17-2.0 (m, 2H), 1.91-1.79 (m, 2H), 1.46 (brs, 9H); ESI-MS: m/z 378.03 (M+Na)⁺. Intermediate 21: Preparation of 4-chloro-2- 2-(dimethylamino)ethoxy)benzoic acid:

Step 1: Synthesis of methyl 4-chloro-2-(2-(dimethylamino)ethoxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.0 g, 10.718 mmol, 1.0 eq) in acetone (20 mL) was added potassium carbonate (7.406 g, 53.59 mmol, 5.0 eq) followed by 2-chloro-N,N-dimethylethan-l -amine hydrochloride (3.08 g, 21.437 mmol, 2.0 eq) and tetra-n-butylammonium bromide (0.690 g, 2.143 mmol, 0.2 eq). The reaction mixture was heated to reflux for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (30 mL) and extracted with DCM (3x50 mL). The combined organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-5% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (2.5 g, yield: 90.57%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.76 (d, = 8.7 Hz, 1H), 7.0-6.95 (m, 2H), 4.17 (t, = 5.4 Hz, 2H), 3.86 (s, 3H), 2.88 (t, = 5.4 Hz, 2H), 2.43 (s, 6H); ESI-MS: m/z 257.94 (M+H)⁺.

Step 2: Synthesis of4-chloro-2-(2-(dimeth lamino)ethoxy)benzoic acid:

To a stirred solution of methyl 4-chloro-2-(2-(dimethylamino)ethoxy)benzoate (step 1, 2.5 g, 9.700 mmol, 1.0 eq) in MeOH (25 mL) was added aqueous IN NaOH solution (77.6 mL, 77.60 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure and acidified with IN HC1 to pH 4. The mixture was evaporated under reduced pressure and then co-distilled with CH₃CN (2x100 mL) and dried under vacuum to obtain the solid (3.0 g). The obtained solid was used as such for next step without further purification. 1H NMR (300 MHz, DMSO-d₆): δ ppm 7.87 (d, = 8.7 Hz, 1H), 7.30 (d, = 1.8 Hz, 1H), 7.14 (dd, = 8.4, 1.8 Hz, 1H), 4.50 (t, = 4.5 Hz, 2H), 3.66 (t, = 4.8 Hz, 2H), 3.05 (s, 6H); ESI-MS: m/z 242.23 (M+H)⁺.

Intermediate 22: Preparation of (S)-4-chloro-2-((tetrahydrofuran-3-yl)oxy)benzoic acid:

Step 1: Synthesis of methyl (S)-4-chloro-2-((tetrahydrofuran-3-yl)oxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.0 g, 10.718 mmol, 1.0 eq) in THF (20 mL) was added (R)-tetrahydrofuran-3-ol (1.88 g, 21.437 mmol, 2.0 eq) followed by triphenylphosphine (5.62 g, 21.437 mmol, 2.0 eq) and diethylazodicarboxylate (5.04 g, 28.940 mmol, 2.7 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with EtOAc (200 mL) and washed with water (100 mL). The organic layer was dried over Na₂S0₄, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-20% ethyl acetate in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.5 g, yield: 54.54%) as a colourless liquid. 1H NMR

(300 MHz, CDC1₃): δ ppm 7.76 (d, J = 8.4 Hz, 1H), 6.98 (dd, J = 8.4, 1.8 Hz, 1H), 6.88 (d, J = 1.8 Hz, 1H), 5.0-4.93 (m, 1H), 4.10-3.85 (m, 7H), 2.24-2.17 (m, 2H); ESI-MS: m/z 256.91

(M+H)⁺.

Step 2: Synthesis of (S)-4-chloro-2-((tetrah drofuran-3-yl)oxy)benzoic acid:

To a stirred solution of methyl (S)-4-chloro-2-((tetrahydrofuran-3-yl)oxy)benzoate (step 1, 1.5 g, 5.843 mmol, 1.0 eq) in MeOH (15 mL) was added aqueous IN NaOH solution (46.75 mL, 46.75 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was neutralized with IN HCl and evaporated under reduced pressure to obtain the title compound (crude wt: 1.2 g) as a white solid, used in next step without further purification. 1H NMR (300 MHz, DMSO-d₆): δ ppm 7.66 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 7.07 (dd, = 7.8, 1.8 Hz, 1H) 5.18-5.13 (m, 1H), 3.94-3.71 (m, 4H), 2.28-2.13 (m, 1H), 2.02-1.95 (m, 1H); ESI-MS: m/z 243.0 (M+H)⁺.

Intermediate 23: Preparation of 4-chloro-2- 2-(pyrrolidin-l-yl)ethoxy)benzoic acid:

Synthesis of l-(2-chloroethyl)pyrrolidine:

To a stirred solution of 2-(pyrrolidin-l-yl)ethan-l-ol (5.0 g, 43.410 mmol, 1.0 eq) in DCM (75 mL) and DMF (5 drops) was added S0C1₂ (17.42 mL, 238.755 mmol, 5.5 eq) at 0 °C. The reaction mixture was heated at 40 °C for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure then cooled to 0 °C, basified with saturated sodium bicarbonate solution and extracted with DCM (2x150 mL). The combined organic layers were washed with water (100 mL), brine solution (20 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 5-8% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.5 g, yield: 25.86%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 3.60 (t, = 6.9 Hz, 2H), 2.82 (t, = 6.9 Hz, 2H), 2.61-2.54 (m, 4H) 1.83-1.77 (m, 4H); ESI-MS: m/z 134.0 (M+H)⁺.

Step 2: Synthesis of methyl 4-chloro-2- 2-(pyrrolidin-l-yl)ethoxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.0 g, 10.718 mmol, 1.0 eq) in acetone (50 mL) was added K₂C0₃ (7.406 g, 53.59 mmol, 5.0 eq) followed by l-(2- chloroethyl)pyrrolidine (step 1, 1.432 g, 10.718 mmol, 1.0 eq) and TBAB (0.690 g, 2.143 mmol, 0.2 eq). The reaction mixture was heated to reflux for 7 hours. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (50 mL) and extracted with DCM (2x50 mL). The combined organic layers were washed with water (50 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 8-10% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.5 g, yield: 49.34%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.76 (d, J = 8.7 Hz, 1H), 7.0-6.94 (m, 2H), 4.24 (t, J = 5.7 Hz, 2H), 3.86 (s, 3H), 3.10 (t, = 5.7 Hz, 2H), 2.90-2.78 (m, 4H), 1.92-1.85 (m, 4H); ESI-MS: m/z 283.67 (M+H)⁺.

Step 3: Synthesis of 4-chloro-2-(2-(p rrolidin-l -yl)ethoxy)benzoic acid:

To a stirred solution of methyl 4-chloro-2-(2-(pyrrolidin-l-yl)ethoxy)benzoate (step 2, 1.5 g, 5.286 mmol, 1.0 eq) in MeOH (15 mL) was added aqueous IN NaOH solution (42.28 mL, 42.28 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was washed with ethyl acetate (30 mL). The aqueous layer was cooled to 0 °C, acidified with IN HCl and evaporated under reduced pressure to obtain the solid. To this solid compound, 20% methanol in DCM (100 mL) was added and stirred at room temperature for 30 minutes. The reaction mixture was filtered and washed with DCM (20 mL). The filtrate was evaporated under reduced pressure to obtain the title compound (1.2 g, yield: 84.2%) as an off- white solid. 1H NMR (300 MHz, CDCI3): δ ppm 11.0 (brs, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.31 (d, = 1.5 Hz, 1H), 7.13 (dd, = 1.8 Hz, 1H), 4.47 (t, = 4.5 Hz, 2H), 3.58 (m, 4H), 3.16 (t, = 8.7 Hz, 2H), 1.98-1.87 (m, 4H); ESI-MS: m/z 270.04 (M+H)⁺.

Intermediate 24: Preparation of 4-chloro-2- 2-(piperidin-l-yl)ethoxy)benzoic acid:

Step 1: Synthesis of l-(2-chloroethyl)pi eridine:

To a stirred solution of 2-(piperidin-l-yl)ethan-l-ol (5.0 g, 38.699 mmol, 1.0 eq) in DCM (50 mL) and DMF (3 drops) at 0 °C was added SOCl₂ (15.52 mL, 212.84 mmol, 5.5 eq) slowly over a period of 30 minutes. The reaction mixture was heated at 40 °C for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (100 mL) and extracted with DCM (3x50 mL). The combined organic layer was washed with saturated sodium bicarbonate solution, dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude compound was purified by silica gel column chromatography by using 0-5% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.7 g, yield: 29.77%) as a colourless liquid. 1H NMR (300 MHz, CDC1₃): δ ppm 3.59 (t, = 7.2 Hz, 2H), 2.69 (t, = 7.5 Hz, 2H), 2.46 (t, = 4.8 Hz, 4H), 1.63-1.56 (m, 4H), 1.47-1.40 (m, 2H); ESI-MS: m/z 148.10 (M+H)⁺.

Step 2: Synthesis of methyl 4-chloro-2- 2-(piperidin-l-yl)ethoxy)benzoate:

To a stirred solution of methyl 4-chloro-2-hydroxybenzoate (2.148 g, 11.513 mmol, 1.0 eq) in acetone (17 mL) was added K₂C0₃ (7.95 g, 57.565 mmol, 5.0 eq), TBAB (0.741 g, 2.302 mmol, 0.2 eq) and 2-(piperidin-l-yl)ethan-l-ol (step 1, 1.7 g, 11.513 mmol, 1.0 eq). The reaction mixture was heated to reflux for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure, diluted with water (50 mL) and extracted with DCM (2x50 mL). The combined organic layer was washed with brine solution (50 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude compound was purified by silica gel column chromatography by using 0-2% methanol in dichloromethane gradient to obtain the title compound (2.72 g, yield: 79.53%) as a colourless liquid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 7.74 (d, = 8.1 Hz, 1H), 6.97 (d, = 8.1 Hz, 1H), 6.94 (s, 1H), 4.19 (t, = 5.7 Hz, 2H), 3.86 (s, 3H), 2.87 (t, = 6.0 Hz, 2H), 2.64-2.57 (m, 4H), 1.72-1.60 (m, 4H), 1.52-1.40 (m, 2H); ESI-MS: m/z 298.11 (M+H)⁺.

Step 3: Synthesis of4-chloro-2-(2-(pi eridin-l-yl)ethoxy)benzoic acid:

To a stirred solution of methyl 4-chloro-2-(2-(piperidin-l-yl)ethoxy)benzoate (step 2, 2.72 g, 9.134 mmol, 1.0 eq) in MeOH (27 mL) was added NaOH (2.92 g, 73.07 mmol, 8.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure. The mixture was cooled to 0 °C, acidified with IN HCl, the precipitates formed were collected by filtration and dried under vacuum to obtain the title compound (1.5 g, yield: 57.9%) as a white solid. 1H NMR (300 MHz, DMSO-d6): δ ppm 13.0 (brs, 1H), 7.73 (d, = 8.4 Hz, 1H), 7.31 (d, = 1.5 Hz, 1H), 7.14 (dd, = 8.4, 1.8 Hz, 1H), 4.52 (t, = 4.5 Hz, 2H), 3.48-3.30 (m, 6H), 1.98-1.40 (m, 6H); ESI-MS: m/z 284.07 (M+H)⁺.

EXAMPLES

Example 1: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl -3a-(2-(4-methoxybenzamido)-2-methylpropanamido)-5a,5b,8,8 J la-pentamethyl-2-oxo-3, 3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaral chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid:

Step 1: Synthesis of 1 -benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-l-isopropyl-3a-(2- ( 4-methoxybenzamido ) -2 -methylpropanamido )-5a, 5b, 8, 8, 1 la-pentamethyl-2-oxo-3, 3a,4, 5, 5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of 4-methoxybenzoic acid (0.295 g, 1.945 mmol, 1.5 eq) in DMF (10 mL) was added HATU (0.739 g, 1.945 mmol, 1.5 eq) followed by TEA (0.9 ml, 6.483 mmol, 5.0 eq). The reaction mixture was stirred at room temperature for 30 minutes, then 1- ((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-amino-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca hydro-2H-cyclopenta[a]chrysen-9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3- dicarboxylate (Intermediate 1, 1.0 g, 1.296 mmol, 1.0 eq) was added and stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (150 mL) and stirred at room temperature for 30 minutes. The precipitates formed were collected by filtration and were washed with water (200 mL) and dried under vacuum to obtain the solid. The resulting solid compound was purified by silica gel column chromatography by using 0-3% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.850 g, yield: 72.42%) as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.73 (d, J = 9.0 Hz, 2H), 7.55 (s, 1H), 7.35 (m, 5H), 6.94 (d, J = 8.7 Hz, 2H), 6.48 (s, 1H), 5.15, 5.09 (ABq, AB = 12.3 Hz, 2H), 4.44 (dd, J = 11.4, 4.5 Hz, 1H), 3.86 (s, 3H), 3.20-3.08 (m, 1H), 2.88-2.58 (m, 5H), 2.38-2.26 (m, 2H), 2.10-2.0 (m, 1H), 2.0-1.81 (m, 3H), 1.81-1.71 (m, 2H), 1.67 (s, 3H), 1.65 (s, 3H), 1.62-1.03 (m, 17H), 1.34 (s, 3H), 1.01 (s, 3H), 0.96 (s, 3H), 0.93 (s, 3H), 0.86 (s, 3H), 0.84 (s, 3H), 0.83 (s, 3H), 0.77 (m, 1H); ESI- MS: m/z 927.56 (M+Na)⁺.

Step 2: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-l-isopropyl-3a-(2- ( 4-methoxybenzamido ) -2 -methylpropanamido )-5a, 5b, 8, 8, 1 la-pentamethyl-2-oxo-3, 3a,4, 5, 5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy) carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-3a-(2-(4-methoxybenzamido)-2-methylpropanamido)-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 1, 0.850 g, 0.938 mmol, 1.0 eq) in MeOH (8.5 mL) and THF (8.5 mL) was added aqueous 2.5N KOH solution (2.81 mL, 7.042 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (20 mL), cooled to 0 °C, pU adjusted to 5.0 with IN HC1 and extracted with DCM (3x50 mL). The combined organic extracts were washed with water (30 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography by using 0-4% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the solid. To this solid compound, ethyl acetate (2 mL) was added and refluxed for 30 minutes. The mixture was cooled to room temperature, heptane (10 mL) was added, stirred at room temperature for 2 hours. The solid was filtered, washed with EtOAc: heptane (1:9, 10 ml) and dried under vacuum to obtain the title compound (130 mg, yield: 16.98%) as an off- white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.73 (d, = 8.7 Hz, 2H), 7.58 (s, 1H), 6.94 (d, = 8.7 Hz, 2H), 6.49 (s, 1H), 4.46 (dd, = 10.8, 4.2 Hz, 1H), 3.86 (s, 3H), 3.22-3.08 (m, 1H), 2.90-2.73 (m, 3H), 2.73-2.50 (m, 2H), 2.40-2.22 (m, 2H), 2.13-2.0 (m, 1H), 2.0-1.83 (m, 3H), 1.81-1.71 (m, 2H), 1.68 (s, 3H), 1.65 (s, 3H), 1.60-1.0 (m, 17H), 1.37 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88-0.82 (m, 9H), 0.78 (m, 1H); ESI-MS: m/z 815.41 (M+H)⁺.

The below examples 2-24 were prepared by the procedure similar to example- 1 by using corresponding intermediates in the presence of suitable reagents, reactants and solvents at appropriate reaction conditions.

Example 2: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-methoxybenzamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8 J la-pentamethyl -2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaral chrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with 4-chloro-2-methoxybenzoic acid followed by hydrolysis gave the desired product as an off-white solid. 1H NMR (300 MHz, CDCI₃): δ ppm 8.18 (s, 1H), 8.11 (d, = 8.4 Hz, 1H), 7.87 (s, 1H), 7.09 (dd, / = 8.7, 1.8 Hz, 1H), 6.99 (d, = 1.8 Hz, 1H), 4.45 (dd, = 11.1, 4.5 Hz, 1H), 3.99 (s, 3H), 3.20-3.05 (m, 1H), 2.89- 2.50 (m, 5H), 2.38-2.18 (m, 2H), 2.10-2.0 (m, 1H), 1.98-1.80 (m, 3H), 1.80-1.69 (m, 2H), 1.65 (s, 3H), 1.60 (s, 3H), 1.59-1.0 (m, 17H), 1.37 (s, 3H), 1.07 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H), 0.85 (m, 9H), 0.81-0.77 (m, 1H); ESI-MS: m/z 849.34 (M+H)⁺. Example 3: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl- 3a-(2-(4-(2-methoxyethoxy)benzamido)-2-methylpropanamido)-5a,5b,8,8 J la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaral chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with Intermediate 2 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.72 (d, = 8.7 Hz, 2H), 7.61 (s, IH), 6.97 (d, = 9.0 Hz, 2H), 6.47 (s, IH), 4.46 (dd, / = 11.4, 4.5 Hz, IH), 4.20- 4.15 (m, 2H), 3.81-3.75 (m, 2H), 3.47 (s, 3H), 3.22-3.10 (m, IH), 2.87-2.50 (m, 5H), 2.38- 2.25 (m, 2H), 2.10-2.0 (m, IH), 2.0-1.82 (m, 4H), 1.80-1.72 (m, 2H), 1.67 (s, 3H), 1.64 (s, 3H), 1.63- 1.40 (m, 5H), 1.37 (s, 3H), 1.40-1.28 (m, 2H), 1.28-1.20 (m, 8H), 1.20-1.10 (m, IH), 1.06 (s, 3H), 1.0 (s, 3H), 0.92 (s, 3H), 0.89-0.83 (m, 9H), 0.81 (m, IH); ESI-MS: m/z 859.58 (M+H)⁺.

Example 4: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl- 5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(2-methyl-lH-benzordlimidazole-5-carboxamido) propanamido)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen- -yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with Intermediate 3 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDCI₃): δ ppm 8.08 (s, IH), 7.77 (dd, = 8.4, 1.5 Hz, IH), 7.54-7.51 (m, IH), 4.45-4.38 (m, IH), 3.25-3.18 (m, IH), 3.01-2.92 (m, IH), 2.88-2.75 (m, 2H), 2.67 (d, = 18.6 Hz, IH), 2.60 (s, 3H), 2.55-2.43 (m, IH), 2.38-2.27 (m, IH), 2.20 (d, = 18.3 Hz, IH), 2.02-1.89 (m, 3H), 1.82-1.60 (m, 3H), 1.58 (s, 3H), 1.57 (s, 3H), 1.54-1.45 (m, 2H), 1.44-1.38 (m, 3H), 1.38-1.32 (m, 3H), 1.34 (s, 3H), 1.31-1.28 (m, 2H), 1.25-1.17 (m, 6H), 1.16-1.05 (m, 1H), 1.01 (s, 3H), 0.96 (s, 3H), 0.93 (s, 3H), 0.89-0.80 (m, 10H); ESI-MS: m/z 839.56 (M+H)⁺.

Example 5: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(lH- benzordlimidazole-2-carboxamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8 J la-penta methyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with lH-benzo[d]imidazole-2-carboxylic acid followed by hydrolysis gave the desired product as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 11.9 (brs, 1H), 8.28 (s, 1H), 7.83-7.70 (m, 2H), 7.50-7.33 (m, 2H), 6.68 (s, 1H), 4.45 (dd, = 11.1, 4.5 Hz, 1H), 3.12-3.02 (m, 1H), 2.90-2.55 (m, 5H), 2.32-2.22 (m, 2H), 2.10- 2.01 (m, 1H), 1.90-1.70 (m, 5H), 1.67-1.50 (m, 9H), 1.45-1.38 (m, 3H), 1.39 (s, 3H), 1.28- 1.15 (m, 10H), 1.09 (s, 3H), 1.01-0.65 (m, 17H); ESI-MS: m/z 847.47 (M+Na)⁺.

Example 6: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl- 5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(6-morpholinonicotinamido)propanamido)-2-oxo- 3,3a,4,5,5a,5b, 6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaralchrysen- 9-yl)oxy)carbonyl)-2 -dimethylcyclobutane- 1-carboxylic acid:

Intermediate 1 was coupled with intermediate 4 followed by hydrolysis gave the desired product as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.58 (d, = 1.5 Hz, 1H), 7.87 (dd, = 9.0, 2.1 Hz, 1H), 7.41 (s, 1H), 6.61 (d, = 9.0 Hz, 1H), 6.46 (s, 1H), 4.46 (dd, = 11.1, 4.2 Hz, 1H), 3.84-3.80 (m, 4H), 3.67-3.59 (m, 4H), 3.20-3.10 (m, 1H), 2.87-2.73 (m, 3H), 2.71-2.53 (m, 2H), 2.38-2.25 (m, 2H), 2.09-1.83 (m, 4H), 1.78-1.58 (m, 5H), 1.66 (s, 3H), 1.64 (s, 3H), 1.47-1.18 (m, 13H), 1.36 (s, 3H), 1.12-1.0 (m, 7H), 0.93 (s, 3H), 0.90-0.77 (m, 10H); ESI-MS: m/z 871.62 (M+H)⁺. Example 7: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl- 5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(3-methyl-lH-pyrazole-5-carboxamido) propanamido)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 5 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.76 (s, IH), 7.11 (s, IH), 6.55 (s, IH), 4.46 (dd, = 11.1, 4.2 Hz, IH), 3.20-3.08 (m, IH), 2.90-2.77 (m, 3H), 2.71-2.53 (m, 2H), 2.37 (s, 3H), 2.36-2.23 (m, 2H), 2.10-1.70 (m, 6H), 1.65 (s, 3H), 1.59 (s, 3H), 1.55-1.15 (m, 17H), 1.37 (s, 3H), 1.07 (s, 3H), 1.0 (s, 3H), 0.92 (s, 3H), 0.89-0.78 (m, 10H); ESI-MS: m/z 789.47 (M+H)⁺.

Example 8: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(6- (1 J-dioxidothiomorpholino)nicotinamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8 J la -pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen- -yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 6 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC13): δ ppm 8.61 (d, = 1.8 Hz, IH), 7.96 (dd, = 9.0, 2.1 Hz, IH), 7.07 (s, IH), 6.77-6.70 (m, 2H), 4.46 (dd, = 10.8, 4.2 Hz, IH), 4.23 (m, 4H), 3.21-3.10 (m, IH), 3.05 (m, 4H), 2.87-2.73 (m, 3H), 2.71-2.52 (m, 2H), 2.38-2.25 (m, 2H), 2.10-2.0 (m, IH), 1.98-1.72 (m, 5H), 1.68 (s, 3H), 1.67 (s, 3H), 1.64- 1.20 (m, 16H), 1.36 (s, 3H), 1.12-1.0 (m, 7H), 0.98-0.77 (m, 13H); ESI-MS: m/z 919.58 (M+H)⁺.

Example 9: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl- 5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(4-(4-morpholinopiperidin- l-yl)benzamido) propanamido)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca vdro-2H- cvclopentaralchrvs -9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 7 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 12.2 (brs, IH), 7.81 (s, IH), 7.73 (d, = 8.4 Hz, 2H), 7.29 (s, IH), 6.93 (d, = 8.7 Hz, 2H), 4.40-4.30 (m, IH), 3.92-3.83 (m, 2H), 3.56 (m, 4H), 3.20-3.13 (m, IH), 2.84-2.72 (m, 6H), 2.60-2.18 (m, 8H), 2.06 (d, = 18.6 Hz, IH), 1.94-1.80 (m, 5H), 1.79-1.08 (m, 20H), 1.41 (s, 3H), 1.40 (s, 3H), 1.31 (s, 3H), 1.0-0.77 (m, 20H).

Example 10: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- ((4-hvdroxypiperidin- 1 - yl)methyl)benzamido)-2-methylpropanamido)- 1 -isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb,12,13,13a-octadecahvdro -2H-cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 8 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.72 (d, = 8.1 Hz, 2H), 7.43 (d, = 7.2 Hz, 2H), 6.58 (s, IH), 4.45 (dd, = 11.1, 4.5 Hz, IH), 3.80-3.70 (m, IH), 3.61 (s, 2H), 3.22-3.08 (m, IH), 2.90-2.53 (m, 7H), 2.40-2.17 (m, 4H), 2.11-1.15 (m, 27H), 1.68 (s, 3H), 1.66 (s, 3H), 1.37 (s, 3H), 1.07 (s, 3H), 1.0 (s, 3H), 0.93 (s, 3H), 0.90-0.77 (m, 10H); ESI-MS: m/z 898.62 (M+H)⁺.

Example 11: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8,l la-pentamethyl-3a-(2-methyl-2-(4-(morpholinomethyl)benzamido) propanamido)-2-oxo-3,3a,4,5,5a, 5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 9 followed by hydrolysis gave the desired product as white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.72 (d, = 7.2 Hz, 2H), 7.42 (d, J = 7.8 Hz, 2H), 7.26 (s, IH), 6.64 (s, IH), 4.46 (dd, / = 11.7, 3.9 Hz, IH), 3.71 (m, 4H), 3.57 (s, 2H), 3.21-3.10 (m, IH), 2.88-2.73 (m, 3H), 2.71-2.55 (m, 2H), 2.46 (m, 4H), 2.38-2.24 (m, 2H), 2.11-0.99 (m, 23H), 1.68 (s, 3H), 1.67 (s, 3H), 1.36 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.97-0.76 (m, 13H); ESI-MS: m/z 884.52 (M+H)⁺.

Example 12: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(4-(((R)-tetrahvdrofuran-3-yl)oxy) benzamido)propanamido)-2-oxo-3,3aA5,5a,5b,6,7 Ja,8,9J0J lJ laJ lbJ2J3 J3a- octadecahydro-2H-cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid:

Intermediate 1 was coupled with intermediate 10 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.73 (d, = 8.7 Hz, 2H), 7.49 (s, IH), 6.89 (d, = 8.7 Hz, 2H), 6.54 (s, IH), 4.99 (m, IH), 4.46 (dd, / = 11.1, 4.5 Hz, IH), 4.07-3.90 (m, 4H), 3.20-3.10 (m, IH), 2.88-2.72 (m, 3H), 2.72-2.52 (m, 2H), 2.38- 2.10 (m, 5H), 2.08-1.83 (m, 5H), 1.80-1.18 (m, 16H), 1.67 (s, 3H), 1.65 (s, 3H), 1.36 (s, 3H), 1.08-1.02 (m, 7H), 0.93 (s, 3H), 0.88-0.77 (m, 10H); ESI-MS: m/z 871.42 (M+H)⁺.

Example 13: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(4-(2-morpholinoethoxy)benzamido) propanamido)-2-oxo-3,3a,4,5, 5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 11 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.72 (d, = 8.7 Hz, 2H), 7.51 (s, 1H), 6.93 (d, = 8.7 Hz, 2H), 6.54 (s, 1H), 4.46 (dd, J = 11.1, 4.2 Hz, 1H), 4.17 (t, = 5.4 Hz, 2H), 3.75 (t, = 5.4 Hz, 4H), 3.22-3.12 (m, 1H), 2.90-2.73 (m, 5H), 2.72-2.50 (m, 6H), 2.38-2.24 (m, 2H), 2.09 -1.82 (m, 5H), 1.80-1.10 (m, 18H), 1.67 (s, 3H), 1.65 (s, 3H), 1.36 (s, 3H), 1.05 (s, 3H), 1.02 (s, 3H), 0.93 (s, 3H), 0.90-0.76 (m, 10H); ESI-MS: m/z 914.59 (M+H)⁺.

Example 14: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(4-((4-methylpiperazin-l-yl)methyl) benzamido)propanamido)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid:

Intermediate 1 was coupled with intermediate 12 followed by hydrolysis gave the desired product as white solid. 1H NMR (300 MHz, CD₃OD): δ ppm 7.99 (d, = 8.1 Hz, 2H), 7.72 (d, = 7.8 Hz, 2H), 7.46 (s, 1H), 4.52-4.40 (m, 3H), 3.80-3.50 (m, 8H), 3.28-3.15 (m, 1H), 3.0 (s, 3H), 2.96 (m, 1H), 2.87-2.79 (m, 2H), 2.65 (d, = 18.6 Hz, 1H), 3.0-2.42 (m, 1H), 2.35-2.27 (m, 1H), 2.19 (d, = 18.3 Hz, 1H), 2.04-1.90 (m, 4H), 1.84-1.10 (m, 19H), 1.57 (s, 6H), 1.35 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.98 (s, 3H), 0.93 (s, 3H), 0.88 (s, 6H), 0.84 (m, 1H); ESI-MS: m/z 897.94 (M+H)⁺.

Example 15: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(4-(((S)-tetrahydrofuran-3-yl)oxy) benzamido)propanamido)-2-oxo-3,3aA5,5a,5b,6,7 Ja,8,9J0J lJ laJ lbJ2J3 J3a-octadeca hvdro-2H-cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 13 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 7.72 (d, = 7.5 Hz, 2H), 7.49 (s, IH), 6.89 (d, J = 7.5 Hz, 2H), 6.52 (s, IH), 4.98 (m, IH), 4.46 (dd, = 10.8, 3.6 Hz, IH), 4.06-3.89 (m, 4H), 3.20-3.10 (m, IH), 2.88-2.72 (m, 3H), 2.72-2.52 (m, 2H), 2.38- 2.21 (m, 3H), 2.18-2.0 (m, 2H), 2.0-1.80 (m, 4H), 1.80-1.0 (m, 18H), 1.67 (s, 3H), 1.65 (s, 3H), 1.37 (s, 3H), 1.06 (s, 3H), 1.02 (s, 3H), 0.88-0.77 (m, 13H); ESI-MS: m/z 893.7 (M+Na)⁺.

Example 16: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8 J la-pentamethyl-3a-(2-methyl-2-(4-(4-methylpiperazin-l-yl)benzamido) propanamido)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cvclopentaralchrvse -9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 14 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CD₃OD): δ ppm 8.05 (s, IH), 7.86 (d, = 8.7 Hz, 2H), 7.45 (s, IH), 7.09 (d, = 8.7 Hz, 2H), 4.45-4.42 (m, IH), 3.60-3.42 (m, 8H), 3.27-3.18 (m, IH), 2.99 (s, 3H), 2.95 (m, IH), 2.90-2.81 (m, 2H), 2.66 (d, = 18.6 Hz, IH), 2.57-2.44 (m, IH), 2.36-2.27 (m, IH), 2.20 (d, = 18.6 Hz, IH), 2.03-1.91 (m, 4H), 1.86- 1.10 (m, 19H), 1.57 (s, 3H), 1.56 (s, 3H), 1.36 (s, 3H), 1.04 (brs, 6H), 0.99 (s, 3H), 0.94 (s, 3H), 0.90 (s, 6H), 0.86 (m, IH); ESI-MS: m/z 905.67 (M+H)⁺.

Example 17: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- (4-hydroxypiperidin-l-yl)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8 J la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 15 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 7.81 (s, 1H), 7.72 (d, = 8.7 Hz, 2H), 7.29 (s, 1H), 6.92 (d, = 8.7 Hz, 2H), 4.69 (m, 1H), 4.40-4.31 (m, 1H), 3.72-3.61 (m, 2H), 3.15-3.05 (m, 1H), 3.02-2.91 (m, 2H), 2.85-2.70 (m, 3H), 2.41-2.20 (m, 4H), 2.06 (d, J = 18.3 Hz, 1H), 1.94-1.73 (m, 6H), 1.73-1.07 (m, 19H), 1.41 (s, 3H), 1.40 (s, 3H), 1.26 (s, 3H), 1.02-0.76 (m, 20H); ESI-MS: m/z 906.41 (M+Na)⁺.

Example 18: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(2-( 1 , 1 -dioxidothiomorpholino)ethoxy)benzamido)-2-methylpropanamido)- 1 - isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13, 13a-octadecahydro-2H-cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid:

Intermediate 1 was coupled with intermediate 16 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.37 (s, 1H), 8.10 (d, = 8.4 Hz, 1H), 7.29 (s, 1H), 7.09 (dd, J = 8.4, 1.5 Hz, 1H), 6.97 (d, J = 1.5 Hz, 1H), 4.46 (dd, J = 11.1, 4.2 Hz, 1H), 4.23 (t, = 5.4 Hz, 2H), 3.20-3.0 (m, 11H), 2.85-2.74 (m, 3H), 2.68- 2.52 (m, 2H), 2.37-2.24 (m, 2H), 2.10-1.74 (m, 6H), 1.69 (s, 3H), 1.65 (s, 3H), 1.61-1.18 (m, 16H), 1.37 (s, 3H), 1.09-1.0 (m, 7H), 0.94-0.78 (m, 13H); ESI-MS: m/z 996.82 (M+H)⁺. Example 19: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(2-methoxyethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8 J la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 17 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.28 (s, 1H), 8.13 (d, = 8.7 Hz, 1H), 7.82 (s, 1H), 7.11 (dd, J = 8.4, 1.5 Hz, 1H), 6.98 (d, J = 1.5 Hz, 1H), 4.47 (dd, J = 11.1, 4.5 Hz, 1H), 4.30-4.24 (m, 2H), 3.83-3.78 (m, 2H), 3.42 (s, 3H), 3.22-3.10 (m, 1H), 2.88-2.76 (m, 3H), 2.73-2.55 (m, 2H), 2.43-2.27 (m, 2H), 2.12-2.01 (m, 1H), 1.98-1.84 (m, 3H), 1.80-1.70 (m, 2H), 1.67-0.95 (m, 17H), 1.63 (s, 3H), 1.62 (s, 3H), 1.39 (s, 3H), 1.09 (s, 3H), 0.92 (s, 6H), 0.99-0.76 (m, 10H); ESI-MS: m/z 893.7 (M+H)⁺.

Example 20: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(((R)-tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-isopropyl-

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca hvdro-2H-cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 18 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC13): δ ppm 12.1 (brs, 1H), 8.63 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.53 (s, 1H), 7.24 (s, 1H), 7.13 (dd, J = 9.9, 1.5 Hz, 1H), 5.29 (m, 1H), 4.39-4.32 (m, 1H), 3.94-3.86 (m, 2H), 3.85-3.71 (m, 2H), 3.18-3.07 (m, 1H), 2.84- 2.70 (m, 3H), 2.41-2.23 (m, 3H), 2.22-2.09 (m, 3H), 2.0-1.83 (m, 3H), 1.82-1.05 (m, 20H), 1.56 (s, 3H), 1.54 (s, 3H), 1.26 (s, 3H), 0.99 (s, 3H), 0.91 (s, 6H), 0.86-0.78 (m, 10H). ESI- MS: m/z 927.58 (M+Na)⁺.

Example 21: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(2-morpholinoethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8 J la -pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 19 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.31 (s, 1H), 8.12 (d, = 8.4 Hz, 1H), 7.82 (s, 1H), 7.08 (dd, J = 8.7, 1.8 Hz, 1H), 6.98 (d, J = 1.8 Hz, 1H), 4.45 (dd, J = 11.1, 4.5 Hz, 1H), 4.23 (t, J = 5.4 Hz, 2H), 3.71 (t, = 4.5 Hz, 4H), 3.20-3.10 (m, 1H), 2.90-2.75 (m, 5H), 2.70-2.60 (m, 2H), 2.58-2.50 (m, 4H), 2.40-2.25 (m, 2H), 2.10-2.0 (m, 1H), 2.0-1.72 (m, 6H), 1.67 (s, 3H), 1.62 (s, 3H), 1.58-1.12 (m, 16H), 1.37 (s, 3H), 1.07 (s, 3H), 0.96 (s, 3H), 0.92 (s, 3H), 0.89-0.75 (m, 10H); ESI-MS: m/z 948.44 (M+H)⁺.

Example 22: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(piperidin-4-yloxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8 J la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid hydrochloride:

Intermediate 1 was coupled with intermediate 20 followed by hydrolysis and BOC deprotection gave the desired product as a white solid. 1H NMR (300 MHz, DMSO-d₆): δ ppm 8.42 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.55 (s, 1H), 7.35 (s, 1H), 7.14 (d, J = 8.1 Hz, 1H), 4.89 (m, 1H), 4.35 (t, J = 7.5 Hz, 1H), 3.20-3.0 (m, 5H), 2.85-2.70 (m, 2H), 2.43-2.25 (m, 3H), 2.20-2.02 (m, 3H), 2.0-1.80 (m, 5H), 1.80-0.97 (m, 27H), 1.26 (s, 3H), 0.97 (s, 3H), 0.90 (s, 3H), 0.89 (s, 3H), 0.86-0.76 (m, 10H); ESI-MS: m/z 918.73 (M-HC1+H)⁺.

Example 23: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(2-(dimethylamino)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb,12,13,13a-octadecahvdro -2H-cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 21 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.37 (s, IH), 8.09 (d, = 8.4 Hz, IH), 7.58 (s, IH), 7.07 (dd, = 8.4, 1.2 Hz, IH), 6.98 (s, IH), 4.49-4.40 (m, IH), 4.28-4.18 (m, 2H), 3.59 (m, 2H), 3.20-3.10 (m, IH), 2.90-2.70 (m, 5H), 2.70-2.50 (m, 2H), 2.40-2.22 (m, 2H), 2.32 (s, 6H), 2.13-1.79 (m, 4H), 1.76-1.68 (m, 2H), 1.64 (s, 3H), 1.61 (s, 3H), 1.57-1.01 (m, 17H), 0.97-0.90 (m, 6H), 0.88-0.76 (m, 13H).

Example 24: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(((S)-tetrahvdrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca hydro-2H-cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Intermediate 1 was coupled with intermediate 22 followed by hydrolysis gave the desired product as a white solid. 1H NMR (300 MHz, CDCI₃): δ ppm 8.19 (s, IH), 8.13 (d, = 8.4 Hz, IH), 7.62 (s, IH), 7.11 (d, = 8.4 Hz, IH), 6.91 (s, IH), 5.11 (m, IH), 4.46 (dd, = 11.1, 4.2 Hz, IH), 4.10-3.90 (m, 4H), 3.20-3.10 (m, IH), 2.88-2.53 (m, 5H), 2.43-2.18 (m, 4H), 2.12-2.02 (m, IH), 1.98-1.80 (m, 4H), 1.77-1.15 (m, 17H), 1.64 (s, 3H), 1.62 (s, 3H), 1.37 (s, 3H), 1.07 (m, 4H), 0.99-0.76 (m, 16H). ESI-MS: m/z 905.60 (M+H)⁺.

Example 25: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(2-(pyrrolidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahvdro-2H-cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l- carboxylic acid:

Intermediate 1 was coupled with intermediate 23 followed by hydrolysis gave the desired product as an off white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.41 (s, 1H), 8.08 (d, = 8.4 Hz, 1H), 7.49 (s, 1H), 7.07 (dd, = 8.4, 1.5 Hz, 1H), 6.98 (d, = 1.5 Hz, 1H), 4.44 (dd, / = 11.1, 4.5 Hz, 1H), 4.38-4.24 (m, 2H), 3.22-3.10 (m, 3H), 2.90-2.70 (m, 7H), 2.69- 2.48 (m, 2H), 2.38-2.20 (m, 2H), 2.06-1.10 (m, 27H), 1.65 (s, 3H), 1.63 (s, 3H), 1.35 (s, 3H), 1.04 (s, 3H), 0.96 (s, 3H), 0.92 (s, 3H), 0.88-0.76 (m, 10H); ESI-MS: m/z 932.44 (M+H)⁺. Example 26: Preparation of sodium (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)- 3a-(2-(4-chloro-2-(2-(piperidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahvdro-2H-cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane-l- carboxylate:

Step 1: Synthesis of 1 -benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(4-chloro-2- (2-(piperidin-l -yl)ethoxy)benz mido )-2-methylpropanamido)-l -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a] chrysen-9-yl) ( 1 R,3S )-2,2-dimethylcyclobutane-l ,3 -dicarboxylate :

To a stirred solution of 4-chloro-2-(2-(piperidin-l-yl)ethoxy)benzoic acid (intermediate 24, 0.441 g, 1.556 mmol, 1.5 eq) in DMF (8 mL) was added HBTU (0.59 g, 1.556 mmol, 1.5 eq) followed by TEA (0.72 mL, 5.187 mmol, 5.0 eq). The reaction mixture was stirred at room temperature for 30 minutes, then 1- ((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-amino-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane- 1,3-dicarboxylate (Intermediate 1, 0.80 g, 1.037 mmol, 1.0 eq) was added and stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (120 mL) and stirred at room temperature for 10 minutes. The precipitates formed were collected by filtration and dried under vacuum. The obtained solid was purified by silicagel column chromatography by using 0-3% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.8 g, yield: 74.41%) as an off-white solid. 1H NMR (300 MHz, CDC1₃): δ ppm 8.32 (s, 1H), 8.12 (d, = 8.4 Hz, 1H), 7.90 (s, 1H), 7.35 (m, 5H), 7.07 (d, 1H), 6.99 (m, 1H), 5.15, 5.09 (ABq, JAB =12.3 Hz, 2H), 4.43 (dd, = 11.1, 4.5 Hz, 1H), 4.30-4.20 (m, 2H), 3.20-3.10 (m, 1H), 2.89-2.60 (m, 8H), 2.50-2.24 (m, 6H), 2.08-1.10 (m, 37H), 1.0-0.76 (m, 19H); ESI-MS: m/z 1036.37 (M+H)⁺. Step 2: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-(4-chloro-2- (2-(piperidin-l -yl)ethoxy)benzamido )-2-methylpropanamido)-l -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a]chryse -9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chloro-2-(2-(piperidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3- dicarboxylate (step 1, 0.8 g, 0.771 mmol, 1.0 eq) in MeOH (8 mL) and THF (8 mL) was added aqueous 2.5N KOH solution (2.31 mL, 5.787 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (10 mL), cooled to 0 °C, ptl adjusted to 5.0 with IN HCl and extracted with DCM (3x50 mL). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-10% methanol in dichloromethane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the solid. To this solid compound, acetonitrile (25 mL) was added and refluxed for 30 minutes. The mixture was cooled to 0 °C, filtered and dried under vacuum to obtain the title compound as an off-white solid (0.125 g, yield: 17.12%) as an off white solid. 1H NMR (300 MHz, DMSO-d6): δ ppm 12.2 (s, 1H), 8.61 (s, 1H), 7.85 (d, = 8.4 Hz, 1H), 7.48 (s, 1H), 7.29 (d, J = 1.2 Hz, 1H), 7.12 (dd, = 8.4, 1.5 Hz, 1H), 4.38-4.32 (m, 1H), 4.25 (m, 2H), 3.19-3.08 (m, 1H), 2.84-2.70 (m, 6H), 2.43-2.10 (m, 6H), 1.98-1.10 (m, 39H), 1.0-0.78 (m, 19H); ESI-MS: m z 946.47 (M+H)⁺.

Step 3: Synthesis of sodium (lR,3S)-3-((((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-(4- chloro-2-(2-(piperidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl- 5 a, 5b, 8,8,11a -pentamethyl-2-oxo -3,3 a, 4, 5, 5 a, 5b, 6,7, 7a, 8, 9, 10,11,1 la, lib, 12, 13,13 a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylate:

To a stirred solution of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (4-chloro-2-(2-(piperidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid (step 2, 0.11 g, 0.116 mmol, 1.0 eq) in methanol (1.09 mL) and water (0.054 mL) was added NaOH (0.0051 g, 0.1278 mmol, 1.1 eq). The reaction mixture was stirred at room temperature for 1.5 hours then distilled out 90% methanol under reduced pressure. Hexane (5 mL) and ethyl acetate (5 mL) were added and the reaction mixture was stirred at room temperature for overnight. The reaction mixture was filtered, solid was washed with hexane (5 mL), followed by ethyl acetate (5 mL) and dried under vacuum to obtain the title compound (0.1 g, yield: 90.9%) as an off-white solid. 1H NMR (300 MHz, CD₃OD): δ ppm 7.93 (d, = 8.4 Hz, 1H), 7.24 (d, = 1.5 Hz, 1H), 7.10 (dd, = 8.4, 1.5 Hz, 1H), 4.32 (m, 1H), 4.30 (m, 2H), 3.25-3.18 (m, 1H), 2.98-2.84 (m, 3H), 2.72-2.48 (m, 8H), 2.43-2.35 (m, 1H), 2.23 (d, = 18.6 Hz, 1H), 2.08-1.18 (m, 38H), 1.10-0.83 (m, 19H); ESI-MS: m/z 968.96 (M+Na)⁺.

Although the present application has been illustrated by certain of the preceding examples, it is not to be construed as being limited thereby; but rather, the present application encompasses the generic area as hereinbefore disclosed. Various modifications and embodiments can be made without departing from the spirit and scope thereof. For example, the following compounds are also included in the scope of the present application and can be prepared by procedure similar to the one described in above synthetic procedures with appropriate variations in reactants, quantities of reagents and reaction conditions.

acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(9H-fluorene-9-carboxamido)-2-methylpropanamido)- 1 - isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(2,3-dihydrobenzo[b][l,4]dioxine-2-carboxamido)-2- methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(benzo[d][l,3]dioxole-5-carboxamido)-2- methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(2,3-dihydrobenzo[b][l,4]dioxine-6-carboxamido)-2- methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2-

(quinoxaline-6-carboxamido)propanamido)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(5-chloro-lH-indole-2-carboxamido)-2-

CI methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

HOCXT octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-

(2-(2,4-dimethoxybenzamido)-2-methylpropanamido)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-

(2-(4-chloro-2-hydroxybenzamido)-2-methylpropanamido)-

1 -isopropyl-5 a,5b,8 , 8,11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(4-chloro-2-(2-(4-methylpiperazin-l- yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-

5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(4-chloro-2-(2-(4-hydroxypiperidin-l- yl)ethoxy)benzamido)-2-methylpropanamido)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-

(2-(4-chloro-2-(2-((R)-3-hydroxypyrrolidin-l- yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-

5a,5b,8,8,l la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-

(2-(4-chloro-2-(2-((S)-2-(hydroxymethyl)pyrrolidin-l- yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-

5a,5b,8,8,l la-pentamethyl-2-oxo- i XF^l ° 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl-5a,5b,8,8,l la-pentamethyl-3a-(2-methyl-2-(4- ,.£,¾VX (methylsulfonamido)benzamido)propanamido)-2-oxo-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(4-((2-(l,l- dioxidothiomorpholino)ethyl)amino)benzamido)-2- methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-

A T pentamethyl-2-oxo-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2- (5 - methyl- 1,3, 4-oxadiazole-2-carboxamido)propan amido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2- (3 - methyl- 1 ,2,4-oxadiazole-5-carboxamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2- ( 1 H- l,2,4-triazole-3-carboxamido)propanamido)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(5-(4-chlorophenyl)-l,3,4-oxadiazole-2-carboxamido)-2- methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-

, £> pentamethyl-2-oxo-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2- (5 - methyl- 1 ,3 ,4-thiadiazole-2-carboxamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2- (5 - methylthiophene-2-carboxamido)propanamido)-2-oxo-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5 a, 5b , 8 , 8 , 11 a-pentamethyl-3 a- (2-methy 1-2-

(thiazole-2-carboxamido)propanamido)-2-oxo-

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-(2-( lH-imidazol- 1 -yl)acetamido)-2- methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-((lS)-3-aminobicyclo[2.2.1]heptane-2-carboxamido)-2-

— *° 0 f^H* methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- o x

octadecahydro-2H-cyclopenta[a]chrysen-9- yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid.

PHARMACOLOGICAL ACTIVITY

The compounds described herein are tested for their antiviral activity following procedures known to a person of ordinary skill in the art. For example, the following protocols can be employed for testing the compounds. These protocols are illustrative and do not limit to the scope of the invention.

Example 27: Evaluation of compounds antiviral activity:

MT2 cells were infected with HIV-1 strain 92HT599 (15TCID 50/ 30000 cells). The infected cells were plated at the concentration of -30 000 cells per well in 96 well plate. Test compound was added to the micro plate in defined format with the final concentration of DMSO (vehicle) is not more than 1%. Assay was carried out with and without human serum/human serum albumin (HSA 45 mg/ml) for the serum shift. Incubation was carried out in C0₂ incubator for - 96 hours for viral infection. At the end of incubation period an aliquot from each well was taken for p24 estimation. The quantitation of p24 is an index for antiviral activity of the compound. Percent inhibition was calculated with reference to control values (vehicle controls).

P-24 estimation was carried out using Advance biosciences kit as per the procedure detailed by supplier.

For 0% serum binding assay, wherein "A" refers to an IC₅₀ value of less than 3 nM, "B" refers to IC₅₀ value in range of 3.01-10 nM, and "C" refers to IC₅₀ values greater than 10 nM. For 45% serum binding assay, wherein "A" refers to an IC₅₀ value of less than 50 nM, refers to IC₅₀ value in range of 50.01-100 nM, and "C" refers to IC₅₀ values greater than nM. The IC₅₀ (nM) values are set forth in Table- 1.

Table- 1

References:

1. Antiviral methods and protocols (Eds: D Kinchington and R. F. Schinazi) Humana Press Inc., 2000.

2. HIV protocols (Eds: N. L. Michael and J. H. Kim) Humana Press Inc, 1999.

3. DAIDS Virology manual from HIV laboratories, Publication NIH-97-3838, 1997.

4. HIV-1 p24 antigen capture assay, enzyme immunoassay for detection of Human immunodeficiency Virus Type 1 (HIV-1) p24 in tissue culture media - Advanced bio science laboratories, Inc kit procedure.

Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as described above.

All publications and patent applications cited in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.

Claims

We Claim: 1. A compound of the formula (I):

Formula (I) wherein,

Ri is substituted or unsubstituted Ci-C₆ alkyl,

or HOOC T , (wherein R_b is selected from hydrogen, substituted or unsubstituted Q-C₆ alkyl, or substituted or unsubstituted C₃-C₈ cycloalkyl);

R₂ is selected from hydrogen, or substituted or unsubstituted Q-C₆ alkyl;

R₃ and R₄ are independently selected from substituted or unsubstituted Q-C₆ alkyl, substituted or unsubstituted amine, substituted or unsubstituted C₃-C₈ cycloalkyl; or R3 and R4 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C₃-C₈ cycloalkyl, epoxide, oxetane, or azetidine;

R5 and R₆ are independently selected from hydrogen, substituted or unsubstituted Q- C₆ alkyl; and R5 and R₆ are taken together to form an oxo group; or R5 and R₆ are taken together with the carbon atom to which they are attached to form a substituted or unsubstitute -C₈ cycloalkyl; ring

is selected from substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heteroaryl, or substituted or unsubstituted heteroarylalkyl; R₇ at each occurrence is independently selected from hydrogen, alkyl, halo, alkoxy, alkoxylalkoxy, haloalkyl, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted C₆-Ci₂ aryl, substituted or unsubstituted 4-15 membered heterocyclyl, substituted or unsubstituted 4-15 membered heterocyclylalkyl, -0(CH₂)_p-heterocyclyl, -O- (CH₂)_q-alkylamino, or substituted or unsubstituted 4-15 membered heteroaryl; wherein the substituents are selected from alkyl, alkylsulfonyl, heterocyclyl, heterocyclylalkyl, hydroxyl, halo, or hydroxylalkyl;

'n' is an integer selected from 1-2;

'm' is an integer selected from 1-3; and

'p' and 'q' independently are an integer selected from 0-2; or

2. The compound according to claim 1, is a compound of the formula (IA):

wherein,

(A )

R2, R3, R₄, R5, R6, R7, ring , 'm' and 'n' are same as defined in claim 1; or pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, rodrugs, or combination thereof.

4. The compound according to claim 1, is a compound of the formula (IC):

wherein,

and 'm' are same as defined in claim 1; or

5. The compound of claim 1-2 wherein R₂ is hydrogen.

6. The compound of claim 1-2 and 5 wherein R₃ and R₄ are substituted or unsubstituted Q-C₆ alkyl.

7. The compound of claim 1-2 and 5-6, wherein R5 and R₆ are taken together to form an oxo group.

8. The compound of claim 1-7, wherein ring ^-^ is substituted or unsubstituted C₆-Ci₂ aryl, or substituted or unsubstituted 4-15 membered heteroaryl.

9. A compound selected from the group consisting of:

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-(4-methoxy benzamido)-2-methylpropanamido)-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a, 8,9,10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)- 2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-methoxy benzamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo-3,3a, 4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-(4-(2- methoxyethoxy)benzamido)-2-methylpropanamido)-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5, 5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid, (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(2-methyl-lH-benzo[d]imidazole-5-carboxamido)propanam -2-oxo-3,3a,4,5,5a,5b, 6,7 ,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(lH-benzo[d]imidazole- 2-carboxamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo-3,3a,4, 5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(6 morpholinonicotinamido)propanamido)-2-oxo-3,3a,4,5,5a,5b, 6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy) carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(3-methyl-lH-pyrazole-5-carboxamido)propanamido)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(6-(l,l-dioxidothio morpholino)nicotinamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-pentam oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(4-morpholinopiperidin-l-yl)benzamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-((4-hydroxypiperidin- l-yl)methyl)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)

pentamethyl-3a-(2-methyl-2-(4-(morpholinomethyl)benzamido)propanamido)-2-oxo-3 5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(((R)-tetra ydrofuran-3-yl)oxy)benzamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadeca ydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(2-morpholinoethoxy)benzamido)propanamido)-2-oxo- 3,3a,4,5, 5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-((4-methylpiperazin-l-yl)methyl)benzamido)propanamido)- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(((S)-tetra ydrofuran-3-yl)oxy)benzamido)propanamido)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-methyl-2-(4-(4-methylpiperazin-l-yl)benzamido)propanamido)-2-oxo- 3,3a, 4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-(4-hydroxypiperidin- l-yl)benzamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo-3,3a, 4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzam

l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro- 2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-methoxy ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid, (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- morpholinoethoxy)benzamido)-2-methylpropanamido)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-((l-(tert-butoxy carbonyl)piperidin-4-yl)oxy)-4-chlorobenzamido)-2-methylpropanamido)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca hydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-(dimethyl amino)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid; and

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid,

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid, and sodium (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- (piperidin-l-yl)ethoxy)benzamido)-2-methylpropanamido)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylate, or

10. A pharmaceutical composition comprising a compound according to any one of claims 1-9 and at least one pharmaceutically acceptable excipient.

11. The pharmaceutical composition according to claim 10, wherein the pharmaceutically acceptable excipient is a carrier or diluent.

12. A method for preventing, ameliorating or treating a viral mediated disease, disorder or syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-9.

13. The method according to claim 12, wherein the viral mediated disease, disorder or syndrome is HIV infection, HBV infection, HCV infection, a retroviral infection genetically related to AIDS, respiratory disorders (including adult respiratory distress syndrome (ARDS)), inflammatory disease, or a combination thereof.

14. A method of treating HIV in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-9.

15. The method according to claim 12 and 14, wherein the subject is a mammal including human.

16. Use of a compound according to any of claims 1-9, in the manufacture of a medicament for the treatment of viral mediated diseases.